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Background: In the last 15 years, rates of prescription opioid addiction and overdose have risen 
rapidly, leading the CDC to label prescription drug overdose a national epidemic. Social stigma 
toward persons with opioid addiction is an important barrier to the advancement of public health-
oriented solutions to this problem. Particular sub-populations, such as pregnant women, may face 
added stigma due in part to perceptions of risk associated with prenatal drug exposure and the 
way in which the problem has been framed in the public discourse. The Affordable Care Act 
(ACA) includes components to expand access to substance use treatment and integrate primary 
care and behavioral health services through reforms to the delivery system, such as the Medicaid 
health home. Maryland is one of only three states to implement health homes in opioid treatment 
programs (OTPs).  
 
Methods: To assess stigma toward persons with prescription opioid addition, I analyzed data from 
a nationally representative public opinion survey fielded in early 2014 (N=1,111). To examine 
how narratives framing prescription opioid addiction during pregnancy affect public attitudes, I 
designed and conducted a randomized experiment with participants drawn from a nationally 
representative web-based panel (N=1,620). To assess the implementation of health homes in 
Maryland OTPs, I conducted in-depth interviews with OTP leadership staff and state officials.  
 
Results: Stigma toward persons with prescription opioid addiction is associated with internal 
causal attributions and with greater support for punitive policy and lower support for public 
health-oriented policy. The degree to which narratives portraying a woman addicted to 
prescription opioids during pregnancy affect public attitudes depends on the socioeconomic status 




OTPs have adopted Medicaid health homes. Among those OTPs that have, interpersonal 
relationships and patient engagement are factors critical to successful implementation. 
 
Conclusions: Social stigma toward persons with prescription opioid addiction has important 
policy implications. Re-framing the issue may reduce stigma and increase support for public 
health-oriented approaches to addressing opioid addiction. OTPs offer a unique opportunity to 
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Prescription opioids are narcotic analgesics (i.e., pain relievers) that include such 
medications as hydrocodone (e.g., Vicodin), oxycodone (e.g., OxyContin, Percocet), morphine, 
and codeine.
1
 These drugs are chemically similar to heroin.
2
 Since the 1990s, prescription opioid 
misuse, addiction and overdose rates have risen dramatically, with the Centers for Disease 
Control and Prevention (CDC) labeling this problem one of the worst drug overdose epidemics in 
U.S. history.
3,4
 Prescription opioid overdose mortality rates have increased nearly four-fold from 
1.4 per 100,000 population in 1999 to a peak of 5.4 per 100,000 population in 2011, when there 
were 16,917 deaths attributed to these medications.
5
 In 2008, drug poisoning deaths surpassed 
motor vehicle accidents as the leading injury-related cause of death in the U.S., and prescription 




Emergence of the problem 
Research published in the 1980s and 1990s challenged the prevailing reluctance among 
physicians to prescribe opioid medications for non-cancer pain.
3
 Although the studies had small 
sample sizes and other methodological limitations, their conclusions advanced the argument that 
prolonged use of these medications was unlikely to cause addiction in patients with no history of 
substance use.
3,8–10
 During the 1990s, the American Academy of Pain Medicine, American Pain 
Society, Joint Commission, and Veterans Health Administration urged medical professionals to 
devote greater attention to pain, which they promoted as the fifth vital sign.
3,11,12
 Meanwhile, the 
pharmaceutical industry sought to fill the niche for pain treatment.
13
 In 1996, Purdue Pharma 
introduced the medication OxyContin, a sustained-released oxycodone medication. Through an 




training in pain management, Purdue Pharma increased sales of OxyContin from $48 million to 
$1.1 billion in four years.
14
 OxyContin became heavily misused, initially in rural areas of the U.S. 
such as the Appalachian states of West Virginia, southwest Virginia and Kentucky.
14
 In 2007, 
Purdue Pharma was ordered to pay over $600 million, one of the largest settlements at that time 
for a pharmaceutical company, for misbranding and minimizing OxyContin’s addictive 
potential.
15
 Although Purdue Pharma released a tamper-resistant product in 2010,
16
 OxyContin 
remains perhaps the most notorious example of the addictive risks of these medications.
17
  
Overall prescribing of opioid medications has exceeded growth in the U.S. population.
2,18
 
Between 1999 and 2013, the amount of dispensed prescription opioids in the U.S. quadrupled.
4
 
Worldwide, the U.S. consumes the vast majority of these products, close to 100 percent of 
hydrocodone and 80 percent of oxycodone.
2
 Substantial prescribing and supply increases have 
been linked to the rising rates of addiction and overdose in the U.S.
2,19–21
 Yet recent evidence 
suggests a possible turning point in the epidemic. Since 2010, rates of opioid prescribing have 
stabilized,
18
 and from 2011 to 2012, mortality from prescription opioid overdose declined (by 5 
percent) for the first time in over a decade.
5
 Yet during that same two-year period, rates of 
overdose deaths from heroin increased by 35 percent.
5
 Research has shown that a portion of 
individuals with prescription opioid addiction have begun transitioning to heroin due to cost and 
availability.
16,22,23
 Four in five persons with new addictions to heroin reported first having 
regularly used prescription opioids.
24
  
Socio-demographic characteristics associated with higher risk of overdose from 
prescription opioids include: male sex, middle-aged, non-Hispanic white, lower income, co-
occurring mental health disorder, and residence in a non-urban community.
3,19,25
 Although 
absolute overdose rates have been higher among men, women experienced a more rapid increase 
between 1999-2010.
26
 Increases in prescription opioid use among women of reproductive age and 
during pregnancy have raised concern given implications for maternal health and birth 
outcomes.
27–30




treatment admissions for heroin addiction and deaths from heroin overdose are more prevalent 
among people who are white, live in non-urban areas, and are older at the age of first use 





Efforts to reduce prescription opioid misuse and addiction have included: mass 
educational campaigns, strengthening regulation of pain clinics, revising clinical guidelines for 
pain treatment, altering insurance and pharmacy benefits, encouraging safe storage and disposal, 
developing tamper-resistant opioid medications, and requiring clinicians to use prescription drug 
monitoring programs (PDMPs).
16,31,32
 Given the huge increases in rates of opioid addiction, 
secondary and tertiary prevention strategies are strongly needed as well.
3,33
 These involve 
improvements in access to evidence-based treatments for opioid addiction including medication 
assisted treatment (MAT), which includes maintenance treatment with methadone or 




A large body of literature has established methadone as an effective treatment for opioid 
addiction that is associated with improved health outcomes, decreased criminal activity, and 
lower overdose mortality, although most of this research has focused on treatment for heroin 
addiction.
34,35
 Methadone maintenance therapy (MMT) is delivered within opioid treatment 
programs (OTPs), which require most patients to make daily visits to obtain their methadone 
doses. In 2002, the Food and Drug Administration (FDA) approved buprenorphine for treatment 
of opioid dependence; buprenorphine can be delivered in an office-based setting by certified 
physicians.
36
 Despite the evidence base, MAT is underused in treatment of opioid addiction. Of 
the more than 2.5 million Americans reporting opioid use disorders in the 2012 National Survey 






A more tertiary method of addressing prescription opioid addiction is with harm 
reduction strategies, such as broader distribution of naloxone (brand name Narcan).
31
 Naloxone is 
a medication that reverses the effects of an opioid overdose and can be administered through 
injection or intranasal methods. Other harm reduction strategies have included implementation of 
immunity laws, which protect persons experiencing an opioid overdose from drug-related 




Barriers to implementing public health-oriented policy 
Barriers to advancing more public health-oriented solutions to opioid addiction (as 
opposed to more punitive approaches) include social stigma toward persons with substance use 
disorders, stigma surrounding MAT, and the historic segregation of behavioral and non-
behavioral health care (often referred to as somatic medical care) in the U.S. health care 
infrastructure. It is possible that the U.S. public feels lower levels of stigma toward persons with 
prescription opioid addiction because these are legal medications and there is an iatrogenic 
pathway to addiction among a portion of users. These factors may reduce internal attributions
37–39
 
for the causes of prescription opioid addiction. However, no study of which we are aware has 
examined the extent to which the American public holds stigmatizing attitudes toward this 
population and whether stigma affects the types of policies that the public supports.  
Subpopulations, such as pregnant women who use substances, are particularly vulnerable 
to social stigma, which has implications for their access to and use of evidence-based 
treatment.
40–42
 Twenty five years ago, the public outcry over “crack babies” elicited a moral panic 
that framed women affected by cocaine addiction as immoral, negligent mothers and their 
children as irrevocably damaged.
43
 Subsequent research on outcomes among cocaine-exposed 
children found many of these claims to be exaggerated and untrue.
44
 Rapidly rising rates of opioid 
withdrawal in newborn infants has drawn attention to the prevalence of prescription opioid use 
during pregnancy.
27,29,30,45




Tennessee passed one of the most punitive laws in the U.S. targeting pregnant women; it enables 
the prosecution of women who use narcotics during pregnancy on criminal child abuse charges.
46
 
As the “crack baby” episode taught us, the framing of substance use during pregnancy by the 
news media and in public dialogue affects how the public views the causes of public health and 
social problems and potential solutions.  
In addition to social stigma and its implications for policy support, the U.S. faces another 
significant barrier to meeting the needs of the growing population with opioid use disorder: 
fragmentation in our health care infrastructure. The historic segregation between behavioral and 
non-behavioral health services is related in part to the high level of stigma toward persons 
suffering from substance use and mental health disorders, which often have been viewed as 
matters of individual character or morality rather than treatable medical conditions.
47–49
 Policy 
changes including the 2008 Mental Health Parity and Addiction Equity Act and the 2010 
Affordable Care Act (ACA) have mandated equitable insurance benefits for substance use 
disorders, first steps toward greater integration.
50
 Yet minimal communication and coordination 
exists between behavioral health and other medical providers regarding patients with substance 
use disorders and other health conditions.
51
 The ACA enables state Medicaid programs to test 
new approaches to integrating behavioral and primary health care, including the Medicaid health 
home. States can apply to implement a health home program in which the federal government 
will provide 90% matching rate (for the first two years) for health home services provided to 
Medicaid enrollees with chronic illnesses, which includes opioid addiction.
51
 At the time of this 
research, Maryland was one of only three states implementing health homes among opioid 
treatment programs.
52
 Little is known about the facilitators and barriers to implementation of 








This dissertation aims to address some of the aforementioned research gaps in order to 
advance public health-oriented solutions to prescription opioid addiction. Paper 1 examines the 
prevalence of social stigma toward persons with prescription opioid addiction by analyzing data 
from a nationally representative survey fielded in early 2014. This study examines the extent to 
which internal and external attributions for prescription opioid addiction affect negative attitudes 
toward this population. In addition, it explores how stigma is associated with the types of policies 
the public supports to reduce prescription opioid misuse and addiction.  
Paper 2 tests whether narratives framing prescription opioid addiction during pregnancy 
affect public attitudes and policy support. In this study, we conducted a randomized experiment in 
which participants are exposed to different versions of a narrative describing a woman who 
becomes addicted to prescription opioids after a car accident and then becomes pregnant. We 
assess how attitudes vary in response to exposure to a narrative portraying the woman as: low or 
high socioeconomic status; facing barriers to addiction treatment access; and successfully 
engaging in treatment for her opioid addiction.  
Finally, Paper 3 describes a qualitative study assessing the implementation of Medicaid 
health homes in Maryland opioid treatment programs. Through in-depth interviews with opioid 
treatment program leadership staff and state officials, we identify facilitators and challenges to 
health home implementation in the opioid treatment program setting. In addition, we examine the 
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Paper 1: Stigma toward persons with prescription opioid addiction and 




In 2008, drug poisonings in the U.S. surpassed motor-vehicle crashes as the leading 
injury-related cause of death nationwide, a shift driven in large part by increasing rates of 
overdose from prescription opioids (i.e., narcotic analgesic medications like OxyContin).
1,2
 The 
problem of prescription opioid misuse and addiction has elicited concern from policymakers, with 
the Centers for Disease Control and Prevention (CDC) labeling prescription drug overdoses a 
national epidemic.
3–5
 However, given that this public health challenge has emerged mainly within 
the last ten years, public attitudes and stigma toward persons with addiction to these medications 
have not been well-studied.
6
 Stigma has important implications for the health and wellbeing of 
affected groups.
7,8
 Research has shown public stigma toward persons with substance use disorders 
(SUD) to be persistently high, exceeding stigma toward those with mental illness or physical 
disability across multiple countries and cultural contexts.
9–12
 The lack of research on stigma 
toward persons with prescription opioid addiction is a noteworthy gap given the substantial 
burden of morbidity and mortality associated with this addiction.
2,13–15
  
Goffman’s seminal work defined stigma as an “attribute that is deeply discrediting” that 
reduces a stigmatized person from “a whole and usual person to a tainted, discounted one.”
16,17
 
Link and Phelan’s sociological conceptualization of stigma includes the interrelated components 
of: labeling the difference that defines the stigmatized group as ‘others’ separated from 
mainstream society; stereotyping or connecting the labeled difference with other negative 
attributes; separating them, the stigmatized persons, from us, mainstream members of society and 
loss of status for the stigmatized group in the social hierarchy as well as discrimination within 
inter-personal relationships and institutional structures.
7,18




noted that stigma depends on the exercise of power, a qualification that distinguishes powerful 
people who may be viewed negatively from those who are stigmatized.
9,18
   
Recent U.S. drug epidemics (e.g., heroin in the 1970s and crack cocaine in the 1980s and 
early 1990s) have been characterized as affecting predominantly low-income racial minority 
populations living in urban settings.
15,19–22
  Linking substance use with populations that already 
experience discrimination may demarcate further those who use substances, an example of the 
“othering” process inherent in stigmatization.
18,23,24
 The current prescription opioid (and related 
heroin) epidemic – in contrast - has disproportionately affected rural and suburban white 
populations,
13,15,25
 a pattern that may have implications for stigma. In addition, the fact that 
prescription opioids are legal medications may affect stigma by reducing associations with 
criminality.
26
 As a target population in the policy-making context, persons with addiction 
traditionally have been socially constructed as deviants because they lack political influence, and 
are viewed unsympathetically by the public.
27
 Policymakers often have pursued punitive action 
toward this group, with minimal objection from other constituencies.
27
  
Another framework through which to examine stigma toward particular groups is 
attribution theory.
12,28–30
 This theory differentiates between causal attributions for a condition that 
emphasize an individual’s disposition or character and attributions that focus on social or 
structural factors.
12
 Research suggests that factors influencing whether persons with a condition 
are stigmatized include the degree to which a condition is perceived as controllable by the 
individual and whether it is viewed as permanent.
12
 Applying attribution theory, we might 
hypothesize that stigma toward persons with prescription opioid addiction might be lower than 
stigma toward persons with other drug addictions because the initial route of exposure to 
prescription opioids can be through an interaction with the health care system for pain treatment 
after an accident or operation,
31
 potentially lowering perceptions that the individual was able to 




The body of literature on stigma toward persons with addiction is more limited than the 
research on stigma toward persons with other mental health conditions.
32
 To address research 
gaps in our knowledge of how the public perceives persons addicted to prescription opioids, we 
conducted a national public opinion survey to measure public attitudes toward this population. 
First, we assessed whether the public associates addiction to these medications with particular 
socio-demographic population groups. Second, we tested the associations between causal 
attributions for prescription opioid misuse and measures of stigma.  Third, we examined the 
associations between attributions of responsibility for addressing the problem and measures of 
stigma. Finally, we examined how public stigma toward persons addicted to prescription opioids 
is associated with support for punitive versus public health-oriented policies aimed at reducing 
the epidemic. Building on prior research,
10,28,29
 we hypothesized that internal causal attributions 
and attributions of responsibility to individuals with addiction would be associated with higher 
levels of stigma. In addition, we hypothesized that stigma would be associated with greater public 
support for punitive policy and lower public support for public health-oriented policies that 







We fielded a survey on public attitudes surrounding the issue of prescription opioid abuse 
to a nationally representative web-based panel from January 31 through February 28, 2014. The 
survey sample was drawn from GfK’s KnowledgeNetworks’® online panel of 50,000 U.S. 
residents, who are recruited through an address-based sampling frame that encompasses 97 
percent of U.S. households.
33
 The recruitment rate for the overall GfK panel was 16.6 percent. 




completed the survey) was 75 percent. Among the respondents completing the survey (N=1,203), 
we excluded those with survey duration times that exceeded two standard deviations above the 
mean survey duration time of 13 minutes (N=65) and respondents with duration times of 5 
minutes or less (N=27). The final analytic sample was 1,111. 
Survey questions asked about: (1) attitudes toward people who are addicted to 
prescription opioids; (2) associations of prescription opioid addiction with particular population 
groups; (3) beliefs about the causes of prescription opioid abuse; (4) beliefs about who is 
responsible for addressing the problem of prescription opioid abuse; and (5) support for various 
punitive and public health-oriented policies to address prescription opioid abuse. Both the order 
of the categories of questions and the order of questions within each category were randomized in 
order to prevent earlier questions influencing responses to later questions in the survey. All 
survey questions used the terminology “prescription pain medication” rather than prescription 
opioid to ensure ease of comprehension. Respondents also read a definition of prescription pain 




Respondent socio-demographic characteristics are collected routinely by GfK for all 
panelists and were provided with the survey data. These socio-demographic data included 
information on respondents’ age, gender, race (white, black, or other race), educational 
attainment (less than high school education, high school or equivalent degree, some college, or 
Bachelor’s degree or higher), household income (less than $10,000, $10,000-24,999, $25,000-
49,999, $50,000-74,999, and $75,000 or greater), residence in a metropolitan statistical area 
(MSA), and political ideology (conservative, moderate, or liberal). The latter three-category 
measure of political ideology was created by collapsing a 7-point Likert scale measure of political 




moderate, or slightly liberal (3, 4, and 5 on the Likert scale) were coded as moderate whereas 
respondents placing themselves on the two ends of the ideology scale were coded either as 
conservative (6 or 7 on the Likert scale) or liberal (1 or 2 on the Likert scale).  In addition, we 
asked respondents if they themselves had ever had a problem with prescription opioid abuse and 
whether they had a family member or close friend who had ever had a problem with prescription 
opioid abuse. We identified those respondents who answered yes to either of these questions as 
having personal experience with prescription opioid abuse. 
To measure stigma, we assessed respondents’ desire for social distance, perceptions 
about the dangerousness of people addicted to prescription opioids, and beliefs about the 
acceptability of discrimination, using items adapted from other surveys.
11,34–36
 Desire for social 
distance was measured using two items asking respondents to assess their level of willingness to 
work closely with a person addicted to prescription opioids or to have a person addicted to 
prescription opioids marry into their family. To assess perceived dangerousness, respondents 
were asked to indicate the extent to which they agreed that people addicted to prescription opioids 
are more dangerous than the general population. Beliefs about the acceptability of discrimination 
were measured via two questions that asked respondents the extent to which they agreed that 
employers should be allowed to deny a job, or landlords should be allowed to deny housing, to 
persons addicted to prescription opioids. All items were measured on 7-point Likert scales. We 
also dichotomized responses to generate descriptive statistics and to conduct sensitivity analyses 
(see analytic approach). Responses of 5 through 7 on the Likert scale were coded as one, and 
responses 1 through 4 were coded zero. In addition, we conducted an exploratory factor analysis 
of the five stigma measures to determine whether the stigma items (measured on the 7-point 
Likert scales) could be scaled together. A stigma scale was constructed by averaging together the 
five individual stigma measures. Given that the five items scaled together had good internal 




To measure associations of this addiction with particular sub-populations, we asked 
respondents to indicate whether they thought that people who are addicted to prescription opioids 
are more likely to be: poor; middle class; wealthy; or if the problem affects people of all income 
groups equally. We also asked about racial and ethnic groups (White/Caucasian, Black/African 
American, Latino/Hispanic, problem affects all groups equally) and geographic residence (rural 
areas, urban areas, suburban areas, problem affects people living in all areas equally).  
To assess causal attributions, we asked respondents to indicate, on 7-point Likert scales 
(from strongly disagree to strongly agree), whether they agreed with statements about the reasons 
people abuse prescription opioids. These items included internal causal attributions, including 
lack of self-discipline and lack of understanding of how easy it is to become addicted to these 
medications, and family history that increases susceptibility to prescription opioid abuse. The 
latter causal attribution does not fall cleanly within the “internal causal attribution” category 
because family history is not a dispositional characteristic nor is it controllable by the individual. 
We also asked about external causal attributions, including: inadequate research on the safety and 
effectiveness of prescription opioids; inadequate explanation of addiction risks by pharmaceutical 
companies; pharmaceutical companies’ promotion of these medications with inadequate 
knowledge of their safety and effectiveness; and health insurance companies’ more generous 
coverage of prescription opioids in comparison to other pain treatments like physical therapy or 
acupuncture. We dichotomized these measures so that responses of 5-7 on the Likert scale 
indicated agreement with the causal statement, and responses of 1-4 indicated lack of agreement 
with the statement. The potential causes of prescription opioid abuse included in the survey were 
identified through a news media content analysis of this topic during the period 1998-2012.
37
  
To measure attributions of responsibility, we asked respondents to indicate, on 7-point 
Likert scales (hardly any to a great deal), how much responsibility the following groups have for 
addressing the problem of prescription opioid abuse in the U.S.: individuals who have become 




and pharmacists; pharmaceutical companies; the government; doctors; health insurance 
companies; and law enforcement. Responses to these questions also were dichotomized so that 
responses of 5-7 on the Likert scale indicated that the group held responsibility for addressing the 
problem while responses of 1-4 indicated that the group held little responsibility. 
To assess policy attitudes, we asked respondents to indicate, on 7-point Likert scales 
(strongly oppose to strongly favor), their support for potential solutions to address prescription 
opioid abuse in the U.S. Policy solutions were gathered from relevant reports produced by the 
Centers for Disease Control and Prevention (CDC),
3
 Trust for America’s Health,
4
 the American 
Medical Association,
38
 and the Office of National Drug Control Policy.
39
 Policy solutions 
examined in this study included one punitive response, arresting and prosecuting people who 
obtain multiple prescriptions for opioid medications at the same time from different doctors 
(known as “doctor-shopping”), in addition to four public health-oriented policies that provide 
support to people addicted to prescription opioids. The latter policies included: expanding 
Medicaid insurance benefits to cover treatment for prescription opioid addiction; passing laws to 
protect people from criminal charges for drug crimes if they are seeking medical help for 
someone experiencing a prescription opioid overdose (i.e., immunity laws); providing naloxone, a 
medication to reverse opioid overdose, to friends and family members of persons addicted to 
prescription opioids; and increasing government spending to improve treatment of substance use 
disorders, including prescription opioid addiction. 
 
Analytic Approach 
We calculated simple descriptive statistics to describe the socio-demographic 
characteristics of the sample. In addition, using the dichotomized measures, we calculated the 
proportion of respondents who expressed stigmatizing attitudes toward persons addicted to 
prescription opioids, including desire for social distance, the perception that they are more 




examine whether the public associates prescription opioid addiction as predominately affecting 
particular sub-populations, we calculated the proportion of respondents who indicated that they 
thought that particular groups (income class, race/ethnicity, area of residence) were more likely to 
be affected by prescription opioid addiction. All analyses incorporated survey weights to account 
for potential sampling bias and non-response. Data was analyzed in Stata 12®.
40
 
To test whether causal attributions and responsibility attributions were associated with 
stigma, we estimated ordered logit regression models. Each binary attribution measure was 
included as the primary independent variable in separate ordered logit regression models in which 
the ordinal stigma measures (on 7-point Likert scales) were the dependent variables. In addition, 
we estimated the associations between each binary attribution measure and the continuous stigma 
scale in ordinary least squares (OLS) linear regression models. To assess the association between 
stigma and support for different types of policies, ordered logit regression models were estimated 
for each policy measure. In these analyses, the ordinal measures of policy support were the 
outcome variables and the independent variable was the continuous stigma scale.  
Drawing from prior research on stigma toward persons with mental illness or a 
SUD,
28,29,32
 all regression models included covariates to adjust for respondent age, gender, race, 
educational attainment, income, MSA residence, and political ideology. In addition, we controlled 
for personal experience with prescription opioid abuse given research indicating that exposure to 
persons with mental illness or addiction may affect stigma.
32,41
 As a sensitivity analysis, we re-
estimated all models using logistic regression replacing the ordinal outcomes with dichotomized 
measures.  
Finally, to determine the extent to which stigma versus socio-demographic characteristics 
and political ideology explained variation among respondents in policy support, we tested 
incremental regression models and compared the R-squared values across these models.
42
 These 
R-squared values provide a measure of how much of the variation in the policy support measures 




values, we estimated linear regression models in which the dependent variables were the ordinal 
measures of policy support, treated as continuous in the OLS regression models in order to 
generate R-squared values. In the first model, we included socio-demographic characteristics of 
respondents: age, gender, race, educational attainment, household income, residence in a MSA, 
and personal experience with prescription opioid abuse. Then, we added a categorical measure of 
a respondent’s political ideology (conservative, moderate, and liberal). Finally, we added the 
stigma scale measure. We compared R-squared values across these three models.  
Results 
 
Table 1 displays the socio-demographic characteristics of the sample. About half of 
respondents were female (52%). Forty-two percent had a high school education or less, 29.3 
percent reported having some college education, and 28.7 percent had a Bachelor’s or more 
advanced degree. The majority of the sample (67%) self-identified as white and about 12 percent 
as African American. Eighteen percent of respondents had household incomes below $25,000 
annually while the largest proportion of respondents had annual household incomes that were 
$75,000 or higher (40.2%). Most (84%) lived in a MSA, which encompasses urban and suburban 
settings. The socio-demographic characteristics of the sample indicate that it is similar to national 
rates based on 2013 Current Population Survey data on observable characteristics (Appendix 1.1). 
In terms of political ideology, 18% of respondents were liberal, 57.6% were moderate, and 24.7% 
were conservative, about the same as rates from the 2012 American National Election Survey 
(ANES). About a third (30%) reported having personal experience with prescription opioid abuse 
either oneself or through a close friend or family member. 
Figure 1 displays the proportion of respondents who expressed negative attitudes toward 
persons addicted to prescription opioids. In terms of desire for social distance, 57.7 percent (95% 
CI: 54.2, 61.2) indicated that they would be unwilling to have a person with an addiction to 




70.9) were unwilling to have someone with this addiction marry into their family. About 56.1 
percent (95% Confidence Interval [CI]: 52.6, 59.6) of respondents thought that people addicted to 
prescription opioids are more dangerous than the general population. Regarding the acceptability 
of discrimination, 55.6 percent (95% CI: 52.1, 59.1) thought that employers should be allowed to 
deny employment, and 39.1 percent (95% CI: 35.6, 42.6) felt that landlords should be allowed to 
deny housing, to a person addicted to prescription opioids.  
Table 2 displays the extent to which the public associates prescription opioid addiction 
with specific population groups. Generally, the public felt that the problem of prescription opioid 
addiction was likely to affect all income groups equally (76.8%), all racial or ethnic groups 
equally (79.8%), and all geographic area of residence groups equally (79.6%). Among the 
minority of respondents (<25%) who associated addiction to prescription opioids with particular 
groups, the largest proportions of respondents associated this addiction with people who are 
middle class (14.6%), white (17.2%), and live in suburban areas (10.0%).  
Table 3 displays results from the ordered logit regression models testing the associations 
between causal attributions for prescription opioid abuse and stigma, adjusting for respondent 
socio-demographic characteristics. Attributing the cause of prescription opioid abuse to 
individual lack of self-discipline was significantly associated with several of the measures of 
stigma. Specifically, respondents attributing the cause of prescription opioid misuse to poor self-
discipline were significantly more likely to: be unwilling to have a person with a prescription 
opioid addiction marry into the family (Coeff: 0.46, 95% CI: 0.16, 0.76), perceive people with 
this addiction as more dangerous than the general population (Coeff: 0.75, 95% CI: 0.43, 1.04), 
and to agree that employers should be allowed to deny employment to a person with this 
addiction (Coeff: 0.40, 95% CI: 0.12, 0.68). Consistent with these findings, the belief that 
prescription opioid abuse was due to a lack of self-discipline was significantly and positively 
associated with the stigma scale measure (Coeff: 0.30, 95% CI: 0.10, 0.51). Support for all of the 




addicted to prescription opioids as dangerous. Attributing the cause of prescription opioid abuse 
to pharmaceutical companies’ promotion of these medications with inadequate knowledge of 
their safety and effectiveness was also significantly and positively associated with the employer 
discrimination measure as well as the stigma scale.  
Attributing responsibility for addressing the problem of prescription opioid abuse to the 
individuals who are addicted to opioid medications was significantly and positively associated 
with all of the individual measures of stigma and the stigma scale (Table 4). Nearly all 
responsibility attributions (except attributing responsibility to pharmaceutical companies) were 
significantly associated with a greater tendency to view persons with this addiction as more 
dangerous than the general population. In addition, attributing responsibility for addressing the 
problem to doctors and to law enforcement was positively associated with several of the 
individual measures of stigma and the stigma scale. 
Table 5 displays findings from the ordered logit regression models testing the 
associations between the stigma scale and support for punitive and public-health oriented policies 
adjusting for respondent socio-demographic characteristics. Respondents expressing greater 
stigma were more likely to support the punitive policy, arresting and prosecuting doctor-shoppers 
(Coeff: 0.53, 95% CI: 0.39, 0.67). In addition, stigma was negatively associated with support for 
several of the public health-oriented policies, including expanding Medicaid insurance benefits to 
cover treatment for prescription opioid addiction (Coeff: -0.15, 95% CI: -0.27, -0.02), passing 
immunity laws to protect persons from drug crime charges if seeking medical assistance for an 
opioid overdose (Coeff: -0.15, 95% CI: -0.26, -0.03), and increasing government spending to 
improve treatment for prescription opioid addiction (Coeff: -0.16, 95% CI: -0.28, -0.03). The 
latter relationships between stigma and support for public health-oriented policies were not 
significant (although they were in the same negative direction) in sensitivity analyses in which 
logistic regression models were estimated using binary measures of policy support as outcomes 




As indicated in Table 5, several of the covariates also were significantly associated with 
policy attitudes, after controlling for stigma and other respondent socio-demographic 
characteristics. For instance, although respondent political ideology was not associated with 
support for the punitive policy, it was significantly associated with attitudes toward all of the 
public health-oriented policies, with self-reported conservatives generally significantly less likely 
than liberals to support these policies. In addition, personal experience (through oneself or a 
family or close friend) was positively associated with support for naloxone distribution (Coeff: 
0.45, 95% CI: 0.16, 0.75). 
When examining the R-squared values in the incremental OLS regression models 
(Appendix 1.5), we found that including the stigma scale substantially improved the models’ 
ability to explain variation in support for the punitive policy, arresting and prosecuting doctor-
shoppers. The R-squared in the models predicting support for this policy was substantially larger 
in the model including stigma (0.136) than in the models with only socio-demographic 
characteristics (0.038) or socio-demographic characteristics and political ideology (0.041). 
However, in the models estimating support for the public health-oriented policies, the largest 
changes in the R-squared values occurred when political ideology was added to the models. 
Adding stigma also increased the R-squared values for these models predicting support for public 




In this nationally representative public opinion survey, we found that persons addicted to 
prescription opioids are highly stigmatized by the public. In the context of other research that has 
used similar measures to assess stigma toward persons with mental illnesses and persons with 
drug addiction,
11
 negative attitudes toward persons with prescription opioid addiction appear to be 




prescription opioid addiction was fairly similar to measures of stigma toward persons with drug 
addiction, although somewhat lower for the measures of the acceptability of discrimination.
11,28
 
Our findings were somewhat surprising for several reasons. First, respondents generally 
did not associate persons who are addicted to prescription opioids with particular income classes, 
racial and ethnic groups, or areas of residence. Among the minority (less than 25%) who did, 
most viewed those more likely to have this addiction to be middle-class, white, and living in a 
suburban area. In other words, while the public generally did not connect prescription opioid 
addiction with populations that have experienced marginalization,
23,24
 a small proportion viewed 
this addiction as affecting more privileged segments of the population. Secondly, because 
prescription opioids are legal medications, we hypothesized that the public would be less likely to 
associate this type of addiction with criminality, reducing stigma. However, we found that 
attributing responsibility to law enforcement was significantly associated with higher levels of 
stigma, which suggests that respondents expressing stigma also may view persons with 
prescription opioid addiction to be criminals or to be engaged in criminal behavior. Third, we 
expected persons with prescription opioid addiction to be less stigmatized than those with drug 
addiction more broadly in part because one of the pathways to this addiction is iatrogenic.
31,43
 
Research indicates that individuals are viewed as more culpable when a situation is foreseeable 
and the action on the part of the individual is intentional.
44
 In fact, we did find that attributing the 
cause of prescription opioid abuse to ignorance about the potentially addictive nature of these 
medications, suggesting less foreseeability, was not significantly associated with higher stigma. 
Our findings generally aligned with other research that has applied attribution theory to 
understand stigma,
10,12,28,29
 indicating that attribution theory is a useful framework through which 
to examine the stigmatization of those with prescription opioid addiction. 71% of respondents 
perceived lack of self-discipline as an important cause of the problem of prescription opioid 
misuse in the U.S. and our study found that this perception was significantly associated with 






 such as a family history that heightens risk of addiction, was not significantly 
associated with stigma. One finding we struggled to explain was the significant association 
between pharmaceutical companies’ inappropriate promotion of these medications and stigma. 
According to attribution theory, we would have expected this relationship to be negative or non-
significant as causal attributions to external factors are not hypothesized to have a positive 
relationship with stigma.  
Our finding that attributions of responsibility to individuals with addiction was associated 
with increased stigma suggests that respondents who view this addiction as controllable feel 
greater stigma toward persons with addiction, a pattern consistent with other research on 
addiction and stigma.
12,29
 Changing these internal attributions of responsibility has the potential to 
reduce stigma toward persons with prescription opioid addiction. Experimental studies have 
demonstrated that reframing problems can alter the degree to which the public attributes 
responsibility to individuals (versus community or governmental actors) for conditions such as 
obesity and poverty.
45–47
 Interestingly, attributions of responsibility to doctors and law 
enforcement were also significantly associated with greater stigma. As noted previously, the 
relationship between attributing responsibility to law enforcement and stigma may be related to 
respondents’ associations of prescription opioid addiction with criminality. However, it is unclear 
why respondents who view doctors as having responsibility to address the problem would hold 
greater stigmatizing attitudes toward persons with this addiction, particularly given efforts over 
the last two decades to reduce stigma toward addiction in part by categorizing it as a chronic 
disease that can be treated by clinicians like other medical conditions.
35,36
  
We found stigma to be a significant factor explaining variation in support for punitive 
policy, even more so than political ideology, which was not a significant predictor. This suggests 
that reducing public stigma toward persons with prescription opioid addiction might be an 
effective way to discourage enactment of punitive policy. In addition, we found significant 




with addiction to prescription opioids. These findings were consistent with other research on 
stigma and policy attitudes,
11
 and indicate that lowering stigma toward persons with addiction to 
prescription opioids may result in increased support for expanded drug treatment access and 
immunity laws to protect persons seeking assistance for drug overdoses.  
 
Limitations 
This study was subject to a number of limitations. Low recruitment rates for online 
survey panels raise concern about external validity of the study findings. However, respondents’ 
socio-demographic characteristics in this study sample were similar to rates nationally; thus, at 
least on observable characteristics, we found no differences between this study sample and the 
national population. Another potential limitation was the use of the term prescription opioid 
abuse in survey questions about causal attributions and responsibility attributions, which may 
have affected responses. Research indicates that referring to a person with a substance use 
disorder as a substance abuser increases stigmatizing attitudes among clinicians,
48
 although it is 
unknown the extent to which this word choice affects attitudes among the public at large. 
However, it is possible that using this terminology may have heightened internal attributions for 
the causes of prescription opioid abuse. This survey assessed public stigma toward persons with 
prescription opioid addiction. Future research could add to our understanding of stigma with 
respect to this population by assessing perceived stigma and self-stigma
32
 and the extent to which 
perceptions of stigma affect this population’s own health and wellbeing, particularly engagement 
with addiction treatment services. Finally, this was a cross-sectional survey so we are unable to 
assess causality or examine mediators of these relationships between attributions and stigma, and 






Among persons with SUDs, perceiving stigma from others and experiencing 
discrimination is associated with riskier behavior, lower psychological well-being, worse physical 
health, and less willingness to disclose substance use to clinicians and engage with addiction 
treatment.
8,32
 Negative attitudes among health care professionals toward persons with SUDs also 
are associated with worse treatment outcomes.
41
 This study is the first of which we are aware to 
assess public stigma toward persons with prescription opioid addiction. We found that stigma 
toward persons with addiction to prescription opioids is high, due at least in part to the public 
attributing the causes to controllable individual factors, such as poor self-discipline, and 
identifying the individuals themselves, as well as doctors and law enforcement to a degree, as 
responsible for addressing the problem. Efforts to reduce stigma are necessary in order to 
discourage public support for punitive responses to the individuals affected by prescription opioid 
addiction, as well as to encourage support for expanding treatment opportunities and harm 
reduction strategies that could benefit this population. Given research indicating a transition from 
prescription opioid use to heroin among a portion of those with opioid addiction,
14,15
 expanding 
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Table 1. Socio-demographic characteristics of respondents  
 
Proportion 95% CI 
Age category   
18-29 years 20.2 (17.0, 23.4) 
30-44 years 25.8 (22.6, 29.0) 
45-59 years 27.5 (24.5, 30.5) 
60 years and older 26.6 (23.7, 29.4) 
Gender (% female) 52.4 (48.9, 55.9) 
Educational attainment   
Less than HS 12.2 (9.8, 14.6) 
High school 29.8 (26.6, 33.0) 
Some college 29.3 (26.1, 32.5) 
Bachelor's degree or higher 28.7 (25.6, 31.9) 
Race   
White 66.9 (63.4, 70.5) 
Black 11.8 (9.4, 14.2) 
Other 21.3 (18.0, 24.5) 
Income category   
Under $10,000 6.1 (4.3, 7.9) 
$10,000-24,999 12.4 (10.1, 14.8) 
$25,000-49,999 22.5 (19.6, 25.4) 
$50,000-74,999 18.7 (15.9, 21.5) 
$75,000 or higher 40.2 (36.7, 43.6) 
Lives in MSA  84.1 (81.5, 86.6) 
Political ideology    
Liberal 17.7 (15.0, 20.4) 
Moderate 57.6 (54.1, 61.1) 
Conservative 24.7 (21.6, 27.7) 
Personal experience with prescription opioid 
abuse 
29.9 (26.6, 33.1) 






0% 10% 20% 30% 40% 50% 60% 70% 80% 
Agree that landlords should be allowed to deny 
housing to a person addicted to prescription 
opioids 
Agree that employers should be allowed to deny 
employment to a person addicted to prescription 
opioids 
Agree that people addicted to prescription 
opioids are more dangerous than the general 
population 
Unwilling to have a person with an addiction to 
prescription opioids start working closely with 
respondent on the job 
Unwilling to have a person with an addiction to 
prescription opioids marry into family 
Figure 1. Negative attitudes toward people addicted to prescription opioids  
 
 
Note: Proportions are estimated using survey weights to reflect attitudes that are nationally representative. 
The 7-point Likert scale measures were dichotomized so that responses 5-7 indicate support for the 







Table 2. Public perceptions about who is affected by prescription opioid addiction 
 
People who are addicted to prescription pain medication 
are more likely to be: 
Proportion 95% CI 
Income group 
  
Poor  4.9 (3.4, 6.3) 
Middle class 14.6 (12.0, 17.2) 
Wealthy 3.8 (2.2, 5.3) 
This problem affects all income groups equally 76.8 (73.7, 79.9) 
Racial or ethnic group  
  
White/Caucasian  17.2 (14.5, 20.0) 
Black/African American 2.2 (1.2, 3.2) 
Latino/Hispanic 0.7 (0.1, 1.4) 
This problem affects all racial and ethnic groups equally 79.8 (76.9, 82.8) 
Area of residence group 
  
Rural areas   1.9 (0.8, 2.9) 
Urban areas 8.5 (6.4, 10.5) 
Suburban areas 10.0 (7.8, 12.3) 
This problem affects all areas groups equally 79.6 (76.7, 82.6) 



















Agree with statement about 
cause of prescription 
opioid misuse 
Unwilling to 
work closely on 
the job with a 






























allowed to deny 






Some people lack the self-




0.129 0.461** 0.733** 0.404** 0.239 0.300** 
[-0.158 - 0.417] [0.163 - 0.759] [0.428 - 1.038] [0.124 - 0.683] [-0.041 - 0.518] [0.096 - 0.505] 
Some people do not 
understand how easy it is to 
become addicted to 
prescription pain 
medication 
0.057 0.212 0.479** 0.232 -0.185 0.133 
[-0.280 - 0.394] [-0.128 - 0.552] [0.159 - 0.799] [-0.117 - 0.581] [-0.530 - 0.160] [-0.108 - 0.374] 
Some people have a family 
history that makes them 
more likely to abuse 
prescription pain 
medications 
-0.069 -0.176 0.602** 0.181 0.141 0.130 
[-0.342 - 0.204] [-0.452 - 0.099] [0.317 - 0.887] [-0.092 - 0.455] [-0.131 - 0.414] [-0.056 - 0.317] 
There has been inadequate 
research on the safety and 







[-0.311 - 0.244] [-0.378 - 0.182] [0.214 - 0.747] [-0.293 - 0.235] [-0.162 - 0.374] [-0.152 - 0.227] 
Pharmaceutical companies 
do not adequately explain 
the risks of addiction on 
labels of prescription pain 
medications 
0.032 -0.050 0.395** 0.185 0.023 0.077 
[-0.232 - 0.296] [-0.327 - 0.228] [0.120 - 0.669] [-0.087 - 0.457] [-0.249 - 0.296] [-0.110 - 0.265] 
Pharmaceutical companies 
promote prescription pain 
medications without 
adequate knowledge of 
their safety and 
effectiveness 
-0.015 0.044 0.686** 0.280* 0.211 0.226* 
[-0.279 - 0.249] [-0.222 - 0.309] [0.429 - 0.944] [0.0200 - 0.540] [-0.050 - 0.472] [0.046 - 0.407] 
Health insurance companies 
are more likely to pay for 
prescription pain 
medication than other pain 
treatments like physical 
therapy or acupuncture 
-0.036 0.066 0.431** 0.187 -0.038 0.095 
[-0.303 - 0.231] [-0.223 - 0.354] [0.156 - 0.706] [-0.089 - 0.463] [-0.313 - 0.238] [-0.099 - 0.290] 
a
 Ordered logit regression coefficients estimate the proportional log odds of being in a higher level of the 7-point Likert scale measuring the stigma attitude 
among those who agree with the causal attribution statement vs. respondents who do not support the causal attribution statement.  
b 
OLS regression coefficients estimate the change in the continuous stigma scale (1-7, non-discrete values) among those who agree with the causal attribution 
statement vs. respondents who do not support the causal attribution statement.  
Ordered logit and OLS regression coefficient estimates all adjust for age, gender, educational attainment, race, household income, MSA residence, political 
ideology, and personal experience with prescription opioids, and incorporate survey weights to account for complex sampling design. 






Table 4. Responsibility attributions for prescription opioid misuse and addiction and measures of stigma toward persons with 
prescription opioid addiction 
 









Attribute responsibility to 
the group for addressing 
the problem of prescription 
opioid abuse 
Unwilling to 
work closely on 
the job with a 






























allowed to deny 






Individuals addicted to 
prescription opioids 
0.392* 0.814** 0.772** 0.687** 0.418* 0.547** 
[0.033 - 0.751] [0.435 - 1.192] [0.386 - 1.159] [0.334 - 1.039] [0.091 - 0.746] [0.285, 0.808] 
Individuals who illegally 
sell prescription opioids 
0.065 0.387* 0.428* 0.268 0.124 0.206 
[-0.257 - 0.387] [0.032 - 0.741] [0.087 - 0.769] [-0.081 - 0.617] [-0.205 - 0.453] [-0.051, 0.463] 
Pharmacies and 
pharmacists 
0.022 0.081 0.414** 0.211 -0.097 0.084 
[-0.257 - 0.300] [-0.201 - 0.363] [0.129 - 0.700] [-0.071 - 0.492] [-0.379 - 0.184] [-0.116, 0.283] 
Pharmaceutical companies 
-0.074 0.155 0.273 0.092 -0.058 0.039 
[-0.356 - 0.208] [-0.128 - 0.438] [-0.008 - 0.553] [-0.184 - 0.367] [-0.347 - 0.232] [-0.160, 0.239] 
Government 
-0.067 0.103 0.345* 0.004 -0.016 0.016 
[-0.331 - 0.197] [-0.168 - 0.374] [0.076 - 0.614] [-0.266 - 0.273] [-0.278 - 0.247] [-0.172, 0.204] 
Doctors 
0.220 0.496** 0.487** 0.327* 0.083 0.251* 
[-0.089 - 0.530] [0.152 - 0.840] [0.168 - 0.805] [0.009 - 0.645] [-0.246 - 0.413] [0.016, 0.486] 
Health insurance companies 
-0.162 -0.002 0.469** 0.100 0.056 0.041 
[-0.429 - 0.106] [-0.272 - 0.269] [0.201 - 0.736] [-0.161 - 0.362] [-0.216 - 0.328] [-0.147, 0.229] 
Law enforcement 
0.070 0.142 0.588** 0.417** 0.294* 0.241** 





 Ordered logit regression coefficients estimate the proportional log odds of being in a higher level of the 7-point Likert scale measuring each stigma attitude 
among those who view the group as responsible for addressing the problem of prescription opioid misuse vs. respondents who do not view the group as 
responsible.  
b 
OLS regression coefficients estimate the change in the continuous stigma scale (1-7, non-discrete values) among those who agree with the causal attribution 
statement vs. respondents who do not support the causal attribution statement.  
Ordered logit and OLS regression coefficient estimates all adjust for age, gender, educational attainment, race, household income, MSA residence, political 
ideology, and personal experience with prescription opioids, and incorporate survey weights to account for complex sampling design. 





Table 5. Association between measures of stigma toward persons with prescription opioid addiction and policy support 
 
 























Passing laws to 
protect people 
from criminal 
charges for drug 



























Stigma scale 0.530** -0.145* -0.148* -0.076 -0.155* 
  [0.386 - 0.673] [-0.272 - -0.018] [-0.263 - -0.034] [-0.210 - 0.058] [-0.280 - -0.029] 
Political ideology (Reference: Liberal) 
     
Moderate -0.242 -0.521** -0.278 -0.331 -0.552** 
  [-0.644 - 0.160] [-0.867 - -0.176] [-0.620 - 0.0633] [-0.697 - 0.0351] [-0.865 - -0.240] 
Conservative -0.118 -1.441** -0.523* -0.744** -1.638** 
  [-0.592 - 0.356] [-1.881 - -1.001] [-0.953 - -0.0931] [-1.178 - -0.310] [-2.080 - -1.197] 
Age (years) 0.006 0.006 0.004 0.003 0.008 
  [-0.003 - 0.014] [-0.002 - 0.014] [-0.003 - 0.0124] [-0.005 - 0.011] [-0.000 - 0.016] 
Female gender 0.088 0.340** 0.010 0.022 0.185 
  [-0.178 - 0.354] [0.087 - 0.593] [-0.255 - 0.275] [-0.246 - 0.290] [-0.074 - 0.443] 
Educational attainment (Reference: high school education) 




  [-0.571 - 0.431] [-0.891 - 0.094] [-0.580 - 0.359] [-0.468 - 0.568] [-0.686 - 0.215] 
Some college -0.122 -0.098 0.036 -0.347 -0.080 
  [-0.471 - 0.227] [-0.436 - 0.241] [-0.298 - 0.370] [-0.697 - 0.003] [-0.420 - 0.261] 
Bachelor's or higher -0.325 0.291 0.386* -0.376* -0.162 
  [-0.689 - 0.039] [-0.0854 - 0.667] [0.010 - 0.761] [-0.748 - -0.005] [-0.539 - 0.216] 
Race (Reference: White) 
     
Black/African American 0.020 -0.085 0.021 -0.033 0.241 
  [-0.433 - 0.474] [-0.505 - 0.335] [-0.392 - 0.435] [-0.484 - 0.418] [-0.175 - 0.657] 
Other race 0.397* 0.151 0.256 0.200 0.267 
  [0.002 - 0.791] [-0.208 - 0.510] [-0.109 - 0.622] [-0.166 - 0.566] [-0.097 - 0.631] 
Household income category (Reference: >$75,000) 
<$10,000 -0.750* 0.267 -0.153 0.298 -0.085 
  [-1.576 - 0.076] [-0.335 - 0.869] [-0.827 - 0.521] [-0.361 - 0.957] [-0.719 - 0.550] 
$10,000-24,999 -0.218 0.207 -0.052 0.349 0.016 
  [-0.705 - 0.268] [-0.222 - 0.637] [-0.511 - 0.407] [-0.126 - 0.824] [-0.431 - 0.464] 
$25,000-49,999 -0.143 0.183 0.009 0.230 0.194 
  [-0.481 - 0.195] [-0.187 - 0.553] [-0.365 - 0.382] [-0.133 - 0.593] [-0.164 - 0.553] 
$50,000-74,999 0.160 -0.015 -0.044 0.141 -0.027 
  [-0.200 - 0.520] [-0.374 - 0.343] [-0.383 - 0.295] [-0.213 - 0.495] [-0.359 - 0.306] 
MSA residence -0.221 0.200 0.086 0.256 0.320 
  [-0.553 - 0.110] [-0.124 - 0.523] [-0.309 - 0.481] [-0.110 - 0.623] 
[-0.0510 - 
0.691] 
Personal experience with prescription 
opioids 
0.228 0.229 -0.079 0.454** -0.007 
[-0.0679 - 0.524] [-0.0608 - 0.520] [-0.370 - 0.211] [0.161 - 0.747] [-0.293 - 0.279] 
       




** p<0.01, * p<0.05 
a
 Ordered logit regression coefficients estimate the proportional log odds of being in a higher level of the 7-point Likert scale measuring each policy attitude with 





Paper 2: Effects of competing narratives on public perceptions of 





Prescription opioid use during pregnancy 
The misuse of prescription opioid pain relievers has emerged as a significant public 
health concern for women over the last decade as rates of addiction and overdose have risen 
rapidly.
1,2
 Prescription opioid use among women has become relatively common. Recent 
estimates show that more than a third of female Medicaid enrollees of reproductive age and over 
a quarter of privately insured women filled at least one prescription for opioid pain relievers 
within the last year.
3
 While these estimates do not distinguish misuse or capture illicit use of 
prescription opioids, they raise concerns about the widespread consumption of these medications 
among women who could become pregnant, given that half of births in the U.S. are unplanned
4
 
and use of these medications during pregnancy is associated with health risks 
3
. A widely-cited 
study published in 2012 also found a significant increase between 2000-2009 in the rate of 
women using opioids near the time of birth;
5
 however, this study also did not distinguish between 
women who were using prescription opioids under the supervision of a clinician and women 
misusing these medications.  
The consensus among medical experts is that pregnant women with an addiction to 
prescription opioids or heroin should receive comprehensive addiction treatment that includes 
opioid maintenance therapy, a type of medication-assisted treatment (MAT).
6,7
 Opioid 
maintenance therapy’s benefits include: reducing fluctuations in opioid levels, protecting the 




relapse; decreasing harmful exposures related to drug addiction; and facilitating greater use of 
prenatal care.
8
 Emerging evidence indicates that infants’ withdrawal symptoms may be less 
severe when women are treated with buprenorphine.
9–12
 However, the standard of care remains 
methadone maintenance given the larger body of research on methadone treatment during 
pregnancy and possibly better treatment retention among those maintained on methadone versus 
buprenorphine.
8,13
 Despite evidence of the benefits of MAT for pregnant women with opioid 
addiction, a minority of these women receive treatment.
14,15
 State Medicaid programs vary widely 
in the extent to which they cover opioid maintenance therapies.
16
 In addition, there is resistance to 




Newborns prenatally exposed to prescription opioids, including methadone or 
buprenorphine within the context of addiction treatment, may experience neonatal abstinence 
syndrome (NAS), a condition that describes the collection of symptoms associated with opioid 
withdrawal. NAS is characterized by signs of nervous system irritability, gastrointestinal 
problems, respiratory distress, and other symptoms.
19
 Nationwide, rates of NAS have risen three-
fold since 2000,
5
 but there is significant geographic variability. For instance, Tennessee has 
experienced nearly a ten-fold increase in the incidence of NAS since 1999.
20
 Although it is a 
treatable condition, many of the newborns diagnosed with NAS require longer hospital stays and 
temporary pharmacologic treatment.
21
 Estimates of the proportion of infants exposed to opioids 
prenatally who are diagnosed with NAS range widely.
21
 The level of NAS severity depends on 
factors such as poly-substance exposure, prenatal care, premature delivery, and secondary 
preventive measures such as swaddling, breastfeeding and keeping the newborn in close physical 









States have undertaken both public health-oriented and punitive measures to attempt to 
reduce NAS and prescription opioid and other substance use during pregnancy.
14,22,23
 Public 
health-oriented strategies have included: educational initiatives (e.g., public service 
announcements), encouraging voluntary prenatal substance use screening and treatment, laws that 
allow immunity from prosecution for drug-related offenses if engaged in drug treatment or 
prenatal care, and prioritizing publicly-funded treatment services for pregnant women. According 
to the Guttmacher Institute, as of 2015, 19 states had targeted drug treatment programs for 
pregnant women, 11 states provided priority access to drug treatment programs for pregnant 
women and 4 states prohibited publicly funded drug treatment programs from discriminating 
against pregnant women, e.g. by refusing them treatment.
22
  
More punitive state actions have included requiring health care providers to report 
mothers of infants diagnosed with NAS to child protective services and categorizing substance 
use during pregnancy as child abuse or as criminal assault.
22,23
 As of 2015, 18 states defined 
substance abuse during pregnancy as child abuse and 15 states required health care providers to 
report pregnant women misusing substances to child protective services,
22
 numbers that have 
increased since 2000.
23
 Tennessee enacted a law in 2014 that allows a woman to be prosecuted 
for aggravated assault if her newborn experiences NAS or if she misuses narcotics (a category 
that includes prescription opioids) while pregnant.
24,25
 Critics of these punitive strategies worry 
about the potentially negative effects on women’s engagement with prenatal care and substance 
use treatment,
26–28
 which improve birth outcomes.
29,30
 Research also indicates that requiring 
health care providers to report drug-using pregnant women to child protective services can have 




Framing the issue of prescription opioid addiction during pregnancy      
The types of solutions that the public perceives as appropriate for addressing NAS and 




consequences of this problem are framed in public discourse. In communication research, Entman 
has defined message framing as “to select some aspects of a perceived reality and make them 
more salient in a communication text, in such a way as to promote a particular problem definition, 
causal interpretation, moral evaluation, and/or treatment recommendation.”
34
 In the context of 
prescription opioid misuse during pregnancy, although risks are associated with pregnant 
women’s health as well 
35
, much of the news media coverage of the issue has focused on NAS. 
Sensationalized news stories have described an epidemic of “oxytots” and “drug-addicted 
babies,”
36–41




In addition to the news media framing the issue mainly in terms of its implications for the 
infant, the enactment of punitive policies targeting mothers in states such as Tennessee
22,43
 have 
led some critics to label this reaction a “moral panic.”
44,45
 Moral panics are situations in which 
segments of the public exaggerate and become sensitized to a perceived threat, with the news 
media often escalating fear and outrage. Blame is attributed to specific segments of the 
population, social deviants who are referred to as “folk devils” by the sociologists who have 
conducted some of the seminal studies of this phenomenon.
46,47
 In the case of prescription opioid 
misuse during pregnancy, the panic surrounds newborns experiencing withdrawal and blame is 
directed toward the mothers. Despite a growing consensus that addiction is a treatable disease 
with behavioral, genetic, and socio-environmental determinants,
48
 these women are often 
perceived as deviants who harm their children intentionally.
44,49
 Attitudes toward pregnant drug-
using women reflect high levels of stigma toward the broader population of people with substance 
use disorders.
50,51
 Much of the American public associates addiction with moral failure rather than 
with a chronic disease that is responsive to treatment.
50,52,53
  
The moral tenor underlying public discourse on substance use is related in part to 
perceptions of people using drugs as “others” who pose a threat to the more virtuous (according 
to mainstream values) members of society.
54




influenced by assumptions and fears about disenfranchised groups, including racial and ethnic 
minorities as well as the poor.
54,55
 Early restrictions on opium were linked to suspicions about 
Chinese immigrants and mandatory federal sentencing for crack cocaine possession was related to 
more negative attitudes toward African American cocaine users compared to white cocaine 
users.
54




It is not clear that perceptions about race or social class have played the same role in 
shaping how the public understands prescription opioid misuse and the related upsurge in heroin 
use. Prescription opioid overdose rates are higher among whites than any other racial and ethnic 
group in the U.S. apart from Native Americans.
57–59
 Public opinion data also suggest that the 
majority of Americans do not perceive the problem of prescription opioid addiction as affecting 
particular racial or ethnic groups or income classes disproportionately.
60
 However, when 
OxyContin initially became popular in Appalachian states, it was dubbed “hillbilly heroin,”
61
 
with clear social class connotations. In addition, Medicaid, the public health insurance program 
for low-income individuals, is the primary payer of NAS-related treatment
5
 and prescription 
opioid use is higher among Medicaid-enrolled women than among privately insured women,
3,62
 
patterns that theoretically could influence public perceptions. However, it is unknown how 
possible preconceptions about who is affected by this problem might change in response to 
exposure to messages frames. One of the few message framing experiments exploring the effects 
of social class cues on public attitudes found that depicting an individual as part of the working 
class versus middle class was associated with reduced perceptions of individual blame for the 
health condition (in this study, diabetes) and increased support for governmental assistance.
63
  
In addition to the public generally associating substance use with particular population 
groups, addiction can also be examined through the lens of attribution theory. Attribution theory 
posits that people understand causes of phenomena in terms of: 1) internality and externality, 2) 
stability and mutability, and 3) controllability.
64,65




characteristics of an individual whereas external causes comprise social and structural forces.
64
 In 
the context of addiction, internal (or dispositional) attributions might include: risk-seeking 
behavior, irresponsibility, and immorality or bad character. In contrast, external (or situational) 
attributions might include: exposure to trauma, iatrogenic factors, and insufficient or inaccessible 
substance use treatment. Internal and external attributions, and the degree to which a condition is 
perceived as stable and controllable, shape how people view potential policy solutions.
66–68
 In the 
context of substance use, even minor differences in labeling a person a substance abuser versus 
someone with a substance use disorder affects perceptions of personal culpability and support for 
punitive policies.
65
    
The discourse in Tennessee during the debates surrounding passage of a law enabling 
criminal prosecution of a woman for assault if she used narcotics during pregnancy (a response to 
increasing rates of NAS in the state) provides one example of how causal attributions in message 
frames can point to particular policy responses. One of the bill’s sponsors, Representative Terri 
Lynn Weaver stated that “[t]hese ladies are not those who would consider going to prenatal care. 
These are ladies who are strung out on heroin and cocaine and their only next decision is how to 
get their next fix. These ladies are the worst of the worst. Again, I want to emphasize what they 
are thinking about, and that is just money for the next high.” Weaver also observed “I don’t know 
what to say about [how] some [women] have insurance and some do not. It’s a terrible thing but I 
don’t want to get into that because that’s another subject.”
43
 In promoting legislation offering a 
punitive solution to substance use among pregnant women, Weaver framed addiction during 
pregnancy as attributable to internal causes, primarily immoral and irresponsible dispositions, and 
dismissed an external factor, lack of health insurance (and by extension, treatment), as a possible 
contributor to the problem. She also framed the issue within the context of illegal drug use even 
though NAS has been linked to rising rates of prescription opioid misuse and addiction. 
In this study, we tested how various narrative depictions of a pregnant woman addicted to 




used by the media, by policymakers, and in educational campaigns to frame social and public 
health issues. Narratives can engage audiences by transporting them into another person’s story 
and can elicit emotional reactions, both features that may enhance receptivity to the narrative’s 
persuasive message.
66,69,70
 Although one study showed that the social class of the person depicted 
in a narrative may affect perceptions of blame for a health condition,
63
 there has been minimal 
research examining the effects of portraying individuals of differing social classes. Research has 
shown that narratives have the potential to increase perceptions that structural determinants 
contribute to the development of stigmatized health conditions, such as obesity, when the 
narrative illustrates external forces influencing an individual.
70,71
 However, the effects of 
narratives portraying barriers to treatment access, which frames untreated addiction as partly 
attributable to external causes, has not been tested. Prior research involving depictions of opioid 
addiction in vignettes (i.e., short narratives)  found that portraying addiction as a treatable 
condition significantly decreased stigma and negative attitudes toward persons with substance use 
disorders, but did not increase support for policies benefitting this population.
52
  
To build on prior research, we conducted a randomized experiment to study the effects of 
exposure to three different narrative features: 1) portrayal of the pregnant woman as high or low 
socioeconomic status (SES), 2) portrayal of the barriers to addiction treatment access during 
pregnancy; and 3) portrayal of a successfully treated pregnant woman. We examined how these 
narratives affected study participants’ beliefs about persons with prescription opioid addiction, 
perceptions of addiction treatment effectiveness, support for public policies to address 
prescription opioid misuse and addiction during pregnancy, and emotional reactions. Emotions 
may be important mechanisms linking message frames more broadly with changes in attitudes 
because these message frames operate through both cognitive and affective channels.
72–75
 
Therefore, we also tested whether emotional responses mediated the relationship between 







A six-group, randomized web-based experiment was fielded to assess the effects of 
exposure to narratives describing a pregnant woman addicted to prescription opioids on beliefs 
about people addicted to prescription opioids, perceptions of treatment effectiveness, policy 
attitudes, and emotional responses. The experiment was fielded September 18 through October 6, 
2014. The sample was drawn from GfK’s KnowledgePanel®, a probability based web panel 
designed to be representative of the U.S. adult population. GfK forms its panel using address-
based sampling from a frame that includes 97 percent of all U.S. households.
76
 When selected 
households lack internet access or a computer, GfK provides these resources so that these 
individuals are not under-represented in the panel. KnowledgePanel® panelists typically take 
around 2 surveys each month and GfK encourages participation by offering cash awards and 
other incentives.
76
 Academic researchers in a number of disciplines, including sociology, political 
science, public health and medicine, have used GfK to field surveys or experimental studies.
77–80
 
Of the KnowledgeNetworks® panelists sampled to participate in the study, 72.8 percent 
completed the experiment. The overall recruitment rate in the KnowledgeNetworks® panel was 
16.6 percent at the time of the study. We dropped 7 participants because their survey completion 
times were potentially too short to ensure adequate time to read the narrative and answer the 
outcome questions. These were participants randomized to read the shorter narratives who took 
less than 2 minutes and participants randomized to read the longer narratives (portraying barriers 
to treatment or treated addiction) who took less than 2.5 minutes to respond. In addition, we 
dropped 36 participants who took more than 4 hours to complete the experiment due to concern 
that these participants did not have sufficiently recent exposure to the narrative prior to answering 




participants took about 13 minutes to complete the experiment. The Johns Hopkins School of 
Public Health Institutional Review Board determined this study to be exempt. 
 
Study Design 
Participants were randomized to one of six groups: a no-exposure control group or one of 
five versions of a narrative about a woman who becomes addicted to prescription opioids after 
suffering injuries from a car accident and becomes pregnant. (Full narratives are presented in 
Appendix 2.1.) Two of the narratives – referred to as the base narratives - examined the effect of 
describing the woman as low versus high socioeconomic status (SES). The low SES base 
narrative read: 
Michelle is a woman in her early twenties who began working at a fast food restaurant after she 
dropped out of high school. She lives in a government-subsidized apartment. Two months ago, 
Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries and she had 
to have surgery. After the surgery, she still had severe pain in her back and hips so her doctor 
prescribed OxyContin, a narcotic pain medication. Three months after her back surgery, she was still 
feeling a lot of pain so her doctor prescribed her a higher dose of OxyContin. Michelle began taking 
more pills to try to control the pain and sometimes ran out before her next refill. When she ran out, she 
felt anxious, became sweaty and nauseous, and had trouble sleeping.  These symptoms lasted until she 
was able to get more pills. Her doctor refused to give her more pills before her next scheduled refill, so 
Michelle sometimes took the bus to other parts of town to get more pills from other doctors. Her 
family and friends noticed that Michelle‘s behavior had changed, and that she was borrowing money 
that she didn’t repay.  When Michelle’s family found out that she was pregnant, they told her that they 
were worried about the pills she was taking and urged her to get help. 
 
The high SES base narrative was identical to the low SES base narrative with the 
exception of the following characteristics. The woman depicted in the high SES base narrative: 
(1) was in her early thirties (and therefore, older at the age of her first pregnancy); (2) worked as 
the regional manager of a restaurant chain (a higher-paying job with greater prestige); (3) had a 
Master’s degree in Business Administration (higher educational attainment); (3) lived in a new 
house (an indicator of wealth); (4) was married when she becomes pregnant; and (5) drove in a 




The narrative with barriers to treatment added the following text to the low SES base 
narrative described above: 
Michelle took the concerns of her family to heart. She was worried that her inability to stop taking 
OxyContin might cause problems during her pregnancy. Michelle’s doctor recommended that she 
begin taking methadone, a medical treatment for addiction, on a daily basis. He explained to Michelle 
that abruptly stopping the OxyContin would cause withdrawal symptoms that might put her health and 
the baby’s wellbeing at risk.  
 
However, when Michelle called a nearby methadone treatment center, they told her that there was a 
long waiting list. Michelle desperately wanted to begin treatment as soon as possible. She found 
another treatment center two hours away that had a spot for her. However, Michelle had trouble getting 
to the treatment center because she didn’t have a car. She felt embarrassed asking friends for help 
because she didn’t want them to know about the problems she was dealing with while pregnant. She 
was grateful to family members who helped out occasionally, but no one could take her every day. 
Taking a taxi was too much money and there was no bus line between the two towns. The nurse at the 
methadone center told her that she needed to be there every day for the treatment to be effective. 
Traveling four hours round-trip on the days she was able to find a ride became exhausting and began to 
create problems for Michelle at work. Her manager became angry when she was repeatedly late for 
shifts and threatened to let her go. Michelle missed days of treatments and began using OxyContin 
again. She felt guilty and ashamed. 
 
We only tested a low SES version of the barriers to treatment narrative (and not a high 
SES version) because many of the barriers included in the text are more relevant to a person with 
limited financial resources, social support, and job flexibility. In order to test the effects of 
portraying successfully treated addiction, we added the following paragraphs to the original low 
and high SES base narratives: 
Michelle took the concerns of her family to heart. She was worried that her inability to stop taking 
OxyContin might cause problems during her pregnancy. Michelle’s doctor recommended that she 
begin taking methadone, a medical treatment for addiction, on a daily basis. He explained to 
Michelle that abruptly stopping OxyContin would cause withdrawal symptoms that might put her 
health and the baby’s wellbeing at risk. Michelle was able to enroll in a methadone program near her 
home. With the help of this program and working with a counselor, Michelle had a healthy 
pregnancy. Her treatment has continued successfully and she hasn’t used OxyContin or other 
narcotic prescription pain medications in over two years. 
 
The face validity of the narrative text and survey instrument was assessed by examining 
how current news media coverage has described pregnant women with prescription opioid 







The independent variable was exposure to one of the five narrative messages or no 
exposure (the control group). We examined how exposure to narratives affected four categories of 
outcome measures: (1) beliefs about people addicted to prescription opioids; (2) perceptions of 
the effectiveness of treatment for addiction to prescription opioids; (3) attitudes about policies to 
address prescription opioid misuse and addiction; and (4) emotional responses. Participants 
randomized to the control group proceeded directly from the introductory screen to questions 
about the extent to which they currently felt four types of emotions. Participants randomized to 
one of the other five groups proceeded from the introductory screen to their randomly assigned 
narrative text before answering questions about their emotions. To assess emotional responses to 
the narratives, we used questions adapted from the validated Positive and Negative Affect Scale 
(PANAS).
81
 Participants indicated, on a 5-point Likert scale, to what extent they felt the emotion 
at that moment. We measured anger, disgust, sympathy and pity.  
Following the questions about emotional responses, all participants read a definition of 
prescription opioids, which were referred to using the less technical term “prescription pain 
medication” throughout the survey; participants also were able to view a list of examples of these 
medications (Appendix 2.2). Then, all participants answered questions about their beliefs about 
people addicted to prescription opioids, perceptions of treatment effectiveness, and support for or 
opposition to potential policy solutions to address prescription opioid misuse and addiction. We 
randomized the order of all question modules as well as the order of questions within each 
module to minimize the potential for bias related to priming, in which responses are influenced by 
exposure to earlier questions in the survey.  
To measure beliefs about people addicted to prescription opioids, participants indicated, 
on a 7-point Likert scale, the extent to which they saw people as completely to blame (or not at all 
to blame) for their drug addiction, as irresponsible (or responsible), and whether or not they 
would be willing to work closely with a person addicted to prescription pain medication, a 
measure of social distance preferences.
50–52




discrimination, we asked participants whether employers should be allowed to deny employment, 
and whether landlords should be allowed to deny housing, to persons addicted to prescription 
opioids.
50–52
 To examine perceptions of treatment effectiveness, participants indicated the extent 
to which they agreed that most people addicted to prescription opioids can, with treatment, get 
well and return to productive lives, and whether they agreed that effective treatment options are 
available to help people who are addicted to prescription opioids.
50–52
 
To test how the narratives affected policy attitudes, we asked participants to indicate, on a 
7-point Likert scale, whether they opposed or favored 6 potential solutions to prescription opioid 
misuse and addiction broadly as well as actions targeting pregnant women specifically. We 
identified policy proposals related to the more general problem of prescription drug abuse from 
the 2013 Trust for America’s Health report on curbing prescription drug abuse.
82
 In addition, we 
identified existing state policies specific to substance use during pregnancy from reports produced 
by the Guttmacher Institute 
22,23




We divided these policies into punitive policies, which include actions that punish 
pregnant women for their addiction, and public health oriented policies, which focus on 
prevention or increased supportive services for this population. Punitive policies included 
defining prescription opioid abuse during pregnancy as criminal child abuse and requiring health 
care providers to report pregnant women abusing prescription opioids to state authorities. Public 
health oriented policies included improving treatment access by prioritizing services for pregnant 
women with addiction, expanding insurance benefits, and passing immunity laws to protect 
pregnant women abusing prescription opioids from being charged with drug crimes if they seek 
treatment. We also tested support for Medicaid lock-in programs in which enrollees suspected of 
misusing prescription opioids are required to use one physician prescriber and/or one pharmacy. 
The latter policy did not fit clearly into the public health oriented or punitive policy category 




these medication (a public health argument in favor of this policy), this inconvenience may be an 
added burden and viewed as punitive toward patients with pain management needs. 
Given research indicating that emotion may be one of the mechanisms through which 
message frames influence perceptions of societal problems and support for policies to address 
these issues,
72,74,75
 we also assessed the emotional response measures as potential mediators.  
 
Analysis 
To assess the representativeness of the sample in comparison to the national population, 
we compared socio-demographic characteristics of the sample participants to data from the 
Current Population Survey (CPS). Weighted socio-demographic characteristics of the analytic 
sample were similar to these national figures (Appendix 2.3).We used chi-square tests to compare 
participants in the six groups on measured socio-demographic characteristics to assess 
randomization. These randomization checks showed no significant differences in characteristics 
across the study groups (Appendix 2.4). Although all outcomes were measured on Likert scales, 
for descriptive purposes, we also collapsed these scales into dichotomized measures (Table 1). 
All analyses were conducted in Stata 12
84
 and included survey weights generated by GfK in order 
to correct for potential biases in sampling and non-response. 
We estimated ordered logistic regression models to assess the effects of the narrative 
exposures on outcomes. Tests of the proportional odds assumption supported the use of ordered 
logistic regression models.
85
 Given that participants were randomly assigned to the narrative 
groups, no covariates were included in the regression models.
86
 In order to test the effects of 
portraying a high or a low SES woman in the narratives, our independent variable in the 
regression models was a categorical measure of exposure to a narrative portraying a low SES 
woman, a narrative portraying a high SES woman, or no exposure. The no exposure control group 
served as the reference category. Wald post-estimation tests were used to assess whether the 




significantly different for participants randomized to read the low SES narrative from those 
randomized to read the high SES narrative.  
Next, to estimate the effects of portraying barriers to treatment, we created binary 
variables in which exposure to the base narrative that did not mention treatment was coded zero 
(the reference category) and exposure to the narrative describing barriers to treatment access was 
coded one. The regression models tested the association between exposure to the narrative 
describing barriers to treatment and the outcomes. We followed the same process to estimate the 
effects of exposure to narratives portraying successfully treated addiction to prescription opioids. 
In these latter analyses, exposure to the high or low SES narrative describing successful treatment 
for addiction was compared to the corresponding high or low SES base narrative that did not 
mention treatment.  
In order to test whether the four emotional responses measured in this survey experiment 
mediated the relationship between the narrative exposure and the other outcomes, we conducted a 
mediation analysis using the Preacher and Hayes approach.
87
 This method enables the testing of 
multiple mediators simultaneously, which was appropriate for our purposes given that 
participants theoretically could have felt more than one emotion at the same time. To produce 
non-symmetric 95% confidence intervals (CIs) around the estimate of the indirect effect through 
the mediator, we used bootstrap resampling.
87
 We identified emotional responses as consistent 
mediators if the indirect effect through the emotion was the same sign (positive or negative) as 
the direct effect estimate. Emotions were deemed inconsistent mediators if the directionality of 
the indirect effect through the mediator differed from that of the direct estimate, which indicated 







Table 1 displays the proportion of participants in the control group (N=264) that 
supported each statement or policy in order to provide a sense of public attitudes at baseline. In 
the control group, slightly more than half of participants thought that people addicted to 
prescription opioids are to blame for their drug addiction (54.4%). A large minority (46.6%) felt 
that employers should be allowed to deny employment to a person addicted to prescription 
opioids and a quarter (26.1%) thought that landlords should be allowed to deny housing. A large 
majority of participants in the control group believed that people addicted to prescription opioids 
could get well with treatment (71.6%), and a majority (67.0%) also felt that effective treatment 
options were available for addiction. In terms of support for punitive policies, close to a third of 
participants in the control group (31.0%) supported prosecuting pregnant women addicted to 
prescription opioids on criminal child abuse charges, and a majority (57.9%) supported requiring 
health care providers to report these women to state authorities, such as child protection services. 
With respect to more public health oriented policies, about half of participants in the control 
group supported immunity laws protecting pregnant women from drug charges if they were 
seeking treatment for their prescription opioid addiction (49.2%) and requiring government-
funded addiction treatment programs to provide priority access for pregnant women (55.1%). 
Among the policies presented in this study, the most popular, with 64.0% support among control 
group participants, was the concept of a lock-in program in which Medicaid enrollees suspected 
of abusing prescription opioids are required to use a single physician prescriber and pharmacy.  
 
Effects of socioeconomic status (SES) in narrative messages on public attitudes 
Table 2 indicates that participants reading the high SES base narrative (N=269) were 
significantly less likely (Coeff: -0.38, 95% CI: -0.70, -0.07) to view people addicted to 
prescription opioids as to blame for their addiction compared to the no-exposure control group, 
whereas there was no difference between the low SES base narrative (N=285) and control group 




and these narratives in measures of desire for social distance from persons with prescription 
opioid addiction or measures gauging the acceptability of discriminating against this group. We 
did find significant differences in beliefs about people addicted to prescription opioids among 
participants randomized to the low SES versus the high SES narrative. Results of Wald tests 
showed significant differences in the high and low SES narrative group coefficients measuring 
less agreement with the statement that people addicted to prescription opioids are irresponsible 
(p-value=0.04) and less desire for social distance measured as unwillingness to work closely with 
people addicted to prescription opioids (p-value=0.01) among those reading the high SES 
narrative compared to those reading the low SES narrative. The same patterns emerged for the 
measures of acceptability of discrimination, in which participants randomized to the high SES 
narrative expressed less agreement with the acceptability of discrimination than those reading the 
low SES narratives.  
We found that those randomized to the high SES base narrative were significantly less 
likely (Coeff: -0.36, 95% CI: -0.69, -0.03) to believe that effective treatment options were 
available to help those addicted to prescription opioids compared to the no-exposure control 
group, whereas those reading the low SES base narrative displayed no difference from the control 
group in their perceptions of treatment effectiveness. Wald tests showed no significant 
differences between the low and high SES narrative groups in perceptions of treatment 
effectiveness. 
Compared to the control group, participants reading the high SES base narrative were 
significantly less likely to support punitive policies but did not demonstrate greater support for 
public health oriented policies. Participants reading the narrative portraying the high SES woman 
had significantly lower levels of support for prosecuting pregnant women addicted to prescription 
opioids on criminal child abuse charges (Coeff: -0.36, 95% CI: -0.69, -0.03) and requiring health 
care providers to report pregnant women who abused prescription opioids to state authorities 




reading the narrative portraying the low SES woman did not differ significantly from the control 
group in their levels of support for these policies. Wald test results showed significantly lower 
support among the high SES narrative participants in comparison to the low SES narrative 
participants for requiring health care providers to report pregnant women to state authorities (p-
value<0.01). Participants in both narrative groups were significantly more likely than the control 
group to support lock-in programs requiring Medicaid enrollees suspected of abusing prescription 
opioids to use a single physician prescriber and pharmacy. The Wald tests found no significant 
differences between the low and high SES narrative group coefficients in levels of support for 
other public health oriented policies. 
Table 2 indicates that participants exposed to both the high and low SES narratives were 
significantly more likely to report stronger emotions than participants in the no-exposure control 
group. The effect of the narrative on the negative emotions – anger and disgust - was stronger 
among participants randomized to the low SES narrative (anger coefficient: 1.26, 95% CI: 0.91, 
1.62; disgust coefficient: 1.36, 95% CI: 1.01, 1.71) than among those randomized to the high SES 
narrative (anger coefficient: 0.83, 95% CI: 0.47, 1.19; disgust coefficient: 0.83, 95% CI: 0.48, 
1.17) (see Table 2). 
 
Effects of portraying barriers to treatment on attitudes 
Table 3 compares attitudes among participants randomized to read the narrative 
portraying a low SES woman facing barriers to treatment (N=268) to those reading the base 
narrative about a low SES woman in which no barriers to treatment were described. Participants 
reading the barriers to treatment version of the low SES narrative were significantly less likely to 
agree that employers should be allowed to deny employment to persons addicted to prescription 
opioids (Coeff: -0.39, 95% CI: -0.70, -0.07) in comparison to participants reading the low SES 




In terms of policy attitudes (see Table 3), compared to those reading the low SES base 
narrative, participants reading the version describing barriers to treatment were significantly less 
likely to support requiring health care providers to report women who have abused prescription 
opioids during pregnancy to state authorities (Coeff: -0.42, 95% CI: -0.74, -0.10), and 
significantly more likely to support expanding Medicaid health insurance benefits to cover 
treatment for prescription opioid addiction (Coeff: 0.31, 95% CI: 0.00, 0.62). Finally, with respect 
to emotional responses, participants reading the low SES narrative depicting barriers to treatment 
reported significantly higher levels of sympathy and pity relative to the low SES base narrative 
(sympathy coefficient: 0.78, 95% CI: 0.46, 1.11; pity coefficient: 0.42, 95% CI: 0.10, 0.74). 
 
Effects of high SES and low SES narratives describing successful treatment on public 
attitudes 
As indicated in Table 4, compared to those randomized to the high and low SES 
narratives with no mention of  treatment, participants reading the narratives depicting successful 
treatment for addiction did not express significantly different beliefs about people addicted to 
prescription opioids. However, the successful treatment narrative did significantly increase the 
belief that most people addicted to prescription opioids can, with treatment, get well and return to 
productive lives, but only among those randomized to read the high SES version (N=274) of this 
narrative (Coeff: 0.37, 95%: 0.04, 0.70). 
In terms of policy attitudes, portraying successfully treated addiction lowered support for 
punitive policies among those randomized to the low SES version of the narrative (N=260). 
Compared to participants reading the low SES base narrative that did not mention treatment, 
participants exposed to the narrative describing successful treatment displayed significantly lower 
levels of support for requiring health care providers to report women who have abused 
prescription opioids during pregnancy to state authorities (Coeff: -0.45, 95% CI: -0.77, -0.12). In 




her addiction expressed significantly lower levels of support for Medicaid lock-in programs 
(Coeff: -0.45, 95% CI: -0.78, -0.12) compared to the low SES base narrative.  
Participants randomized to read the low SES version of the narrative portraying 
successful treatment reported significantly lower levels of anger and disgust compared to those 
reading the low SES base narrative without treatment (anger coefficient: -0.70, 95% CI: -1.04, -
0.35; disgust coefficient: -0.69, 95% CI: -1.03, -0.034). Similarly, participants reading the high 
SES narrative portraying successful treatment reported significantly less anger and disgust 
compared to those reading the high SES base narrative (anger coefficient: -0.45, 95% CI: -0.80, -
0.10; disgust coefficient: -0.52, 95% CI: -0.86, -0.17).  
 
Emotional responses as mediators of the relationship between narrative exposure and 
attitudes 
We found that emotional responses to the narratives partially mediated many of the 
relationships with public attitudes. The mediation analysis demonstrated that by eliciting 
sympathy, the high SES base narrative reduced the extent to which participants perceive 
individuals as to blame for their addiction, compared to the control group. Sympathy was a 
consistent mediator because the indirect effect of the high SES base narrative on participants’ 
attributions of blame to the individuals addicted to prescription opioids was negative, as was the 
direct effect of the narrative on perceptions of blame. However, the high SES base narrative’s 
positive effect on disgust also increased attributions of blame for addiction to individuals. 
Therefore, disgust was an inconsistent mediator because its indirect positive effect blunted some 
of the total negative direct effect of the narrative exposure on beliefs about blame. In other words, 
by generating disgust, the total negative impact of the narrative on perceptions that individuals 
are to blame for their drug addiction was reduced.  
We found that pity mediated the relationship between exposure to the high SES base 




criminal child abuse charges, compared to the control group. By increasing pity, this narrative 
reduced support for this policy. In contrast, anger was an inconsistent mediator of the relationship 
between the high SES base narrative and another punitive policy, requiring health care providers 
to report women abusing prescription opioids to state authorities. Although the total effect of the 
narrative on this outcome was negative (suggesting that the narrative was associated with reduced 
support for the policy), the indirect effect through anger was positive, indicating that anger 
suppressed some of the high SES narrative’s overall negative effect on support for the punitive 
policy. 
Rarely were multiple emotional responses simultaneously consistent mediators of the 
relationship between a narrative exposure and public attitudes. One exception was the low SES 
narrative portraying barriers to treatment, which, in comparison to the low SES base narrative, 
had a positive effect on support for expanding Medicaid benefits to cover treatment for 
prescription opioid addiction.  This relationship was partly mediated by increases in both 
sympathy and pity. Anger and disgust were also simultaneous consistent mediators in one case. 
Compared to the low SES base narrative, the narrative describing successful treatment of a low 
SES woman reduced support for requiring health care providers to report women abusing 
prescription opioids to state authorities partly by lowering participants’ anger and disgust. 
However, lower levels of pity (a significant inconsistent mediator) somewhat blunted the total 
negative effect of the narrative exposure on this outcome. 
Discussion 
 
In this framing experiment involving narratives about a woman struggling with opioid 
addiction in the context of a pregnancy, we found particular aspects of narratives to be important 
in shaping public attitudes: (1) the SES of the woman depicted; (2) the portrayal of barriers to 
treatment access; and (3) the portrayal of successfully treated addiction. These findings provide 




during pregnancy and can inform the development of communication strategies to reduce stigma 
and support for punitive policy, and increase support for more public health oriented approaches 
to addressing this problem.  
Our finding that only the narrative depicting a high SES woman reduced the perception 
that individuals are to blame for their addiction somewhat contradicts the findings of Gollust and 
Lynch,
63
 who found that a portrayal of a working class individual elicited less individual blame 
for an illness (in this case, diabetes) than the portrayal of a middle class individual. However, 
given stereotyping about the poor and drug use,
56,88
 it is possible that the effectiveness of the 
narrative portraying a high SES woman in changing attitudes was due more to its contradiction 
with study participants’ preconceptions about who uses substances during pregnancy rather than 
beliefs about the degree to which members of particular social classes deserve individual blame 
for their health conditions. This interpretation is supported by our finding that portraying a low 
SES woman did not significantly increase negative beliefs about individuals with prescription 
opioid addiction or increase support for punitive policy. Rather, the idea that a woman with a 
good job and high educational attainment, living in a nice house, may nevertheless suffer from 
addiction appears to have caused study participants to reconsider their blame for addiction and 
support for punitive policy targeting this population. In addition to breaking stereotypes, our 
finding that the effectiveness of this narrative in changing perceptions was due in part to its 
elicitation of sympathy and pity contributes to the developing research on the significance of 
emotions in persuasion.
72,73
 Messages that contradict negative stereotypes and engage sympathy 
and pity may be promising communication strategies for reducing stigma and lowering support 
for policies that punish vulnerable populations. 
Our findings suggest that narrative messages portraying a low SES woman placed within 
the broader social context –by describing the challenges she faces while attempting to access 
treatment - may increase support for public health oriented policy. Although Iyengar’s message 




contributing to a social condition like poverty reduce perceptions that collective actors, like the 
government, should play a role in addressing the problem,
89,90
 recent studies have shown that 
narrative portrayals are not intrinsically episodic.
66,70
 Our study adds to this area of research by 
demonstrating that a narrative portraying the structural barriers faced by an individual attempting 
to access treatment can increase support for policies targeting these external factors.  
Portraying successfully treated addiction reduced support for punitive policy and 
increased the perception that treatment can be effective, although these effects varied depending 
on the SES of the woman portrayed in the narrative. Advocates for less punitive drug policy have 
hoped that reframing addiction as a chronic disease, a concept supported by neurological 
research, will reduce public perceptions of addiction as a moral failure, lowering stigma and 
increasing support for more medically-oriented solutions.
91
 There has been disagreement about 
the success of the disease paradigm in reducing stigma.
51,92
 One explanation for why the disease 
paradigm has not resonated more with the public is that people do not believe that the medical 
and public health approaches based on this paradigm have been effective in reducing drug abuse 
and addiction.
91
 However, in our study, the majority of the control group believed that treatment 
options for prescription opioid addiction are available and can be effective. Adding to emerging 
research,
52
 our findings provide additional evidence that individualized depictions of people 
successfully treated for addiction may be one promising avenue for generating greater public 
confidence in available treatments. Public confidence in treatment for addiction is important as 
insurance coverage expansions under the Affordable Care Act reduce some of the financial 





This study had several limitations. While online survey panels are subject to concerns 
related to external validity, GfK’s address-based sampling approach and the application of survey 




comparing the socio-demographic characteristics of our sample to Current Population Survey 
data, we found no difference on observable characteristics (Appendix 2.3), suggesting that 
findings from this study appear to be generalizable to the U.S. public more broadly. The public 
obtains information and news about health and social issues in a number of formats, including but 
not limited to narratives. Nevertheless, individualized narrative depictions are a common way of 
conveying information in news and entertainment media and are employed frequently by 
policymakers attempting to persuade the public to support particular policy proposals. Examining 
the role of narratives can help us to determine whether particular aspects of individualized 
portrayals influence public attitudes surrounding controversial issues.  
Although we intentionally used language to neutralize assumptions about race (e.g., 
giving the pregnant woman a name that is not associated with any specific racial or ethnic group), 
study participants may have inferred race from the indicators of socioeconomic status. Despite 
efforts to limit racial indicators, we cannot definitively state that the differences between 
participant responses among those in the low versus high SES narrative groups were limited to 
perceptions about socioeconomic status only. Another limitation of the content of these narratives 
was the lack of mention of buprenorphine, a medication alternative to methadone increasingly 
used to treat opioid addiction during pregnancy. Stigma associated with methadone may have 
influenced participant responses to the narratives describing treatment. However, we featured 
methadone as the medication treatment in the narrative because although evidence is emerging 
that buprenorphine may reduce the risk of NAS, the standard of care for opioid addiction 
treatment during pregnancy is still methadone.
8
 Future research examining the effects of 
messages framing opioid addiction during pregnancy might explore whether the method of 
treatment, and its reputation, affects public responses.     
 




In a seminal article on moral panics, Goode and Ben-Yehuda note that “the periodic drug 
panics that have washed over American society for a century continue to deposit institutional 
sediment in their wake.”
47
 Concern over withdrawal in infants, without consideration for the 
health and wellbeing of mothers, may contribute to the enactment of punitive policies ,
94
 which 
may further reduce this vulnerable population’s already low engagement with the health care 
system.
26,95
 Anecdotal reports in Tennessee suggest that since the state defined narcotic abuse 
during pregnancy as a form of criminal assault in 2014, women with substance use disorders have 
been crossing state lines in order to obtain health services.
96
 However, there has been no 
empirical research yet on the effects of this law. While some of the narratives in this study were 
associated with lower support for punitive policies, the barriers to treatment narrative was the 
only narrative associated with increased support for a public health oriented policy: expanded 
access to addiction treatment for Medicaid enrollees. Pregnancy offers an opportunity to 
intervene and provide services to a population that may be more motivated to engage with 
addiction treatment at this critical point.
97
 Given that a substantial proportion of child protective 
service cases involve problems related to parental substance use,
98
 treatment during pregnancy 
can be an early preventive measure that increases the odds of future health and wellbeing for 
families coping with addiction.
94
 Efforts to increase support for expanded substance use treatment 
access for this population may consider using narratives to illuminate the barriers to care that 
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Attitudes toward people addicted to prescription pain medication  
People who are addicted to prescription pain medication are to blame for their drug addiction 54.4 (48.0, 60.8) 
People who are addicted to prescription pain medication are irresponsible 46.1 (39.8, 52.5) 
Unwilling to work closely with a person with an addiction to prescription pain medication  45.2 (38.9, 51.5) 
Employers should be allowed to deny employment to a person addicted to prescription pain medication  46.6 (40.3, 53.0) 
Landlords should be allowed to deny housing to a person addicted to prescription pain medication  26.1 (20.4, 31.7) 
Perceptions of treatment effectiveness  
Most people addicted to prescription pain medication can, with treatment, get well and return to productive lives  71.6 (65.8, 77.4) 
Effective treatment options are available to help people who are addicted to prescription pain medication 67.0 (60.9, 73.1) 
Policy attitudes  
Punitive policies  
Prosecute pregnant women who are addicted to prescription pain medication on criminal child abuse charges 31.0 (25.1, 36.9) 
Require health care providers to report women who have abused prescription pain medication during pregnancy to state 
authorities, such as child welfare agencies  
57.9 (51.5, 64.2) 
Public health oriented policies  
Pass immunity laws to protect pregnant women addicted to prescription pain medication from being charged with drug crimes 
if they seek treatment for their addiction.  
49.2 (42.8, 55.6) 
Require government-funded addiction treatment programs to provide priority access for pregnant women.  55.1 (48.8, 61.5) 
Expand Medicaid health insurance benefits for low income families to cover treatment for prescription pain medication 
addiction. 
50.9 (44.5, 57.3) 
Require individuals enrolled in Medicaid health insurance that are suspected of abusing prescription pain medication to use a 
single physician prescriber and single pharmacy. 
64.0 (57.7, 70.2) 
Table displays the percent (%) of respondents who strongly or somewhat endorse statement among no-exposure control group. 7-point Likert scale responses 
were dichotomized so that this table displays the percent of responses that were 5, 6 or 7 on the 7-point Likert scale assessing agreement with statement or 
support for policy. 





Table 2: Effects of socioeconomic status (SES) in portrayals of a pregnant woman on attitudes, compared to the control group (N=818), 
2014 
 





Low SES base 
narrative vs. 
control group 
High SES base 
narrative vs. 
control group 
Attitudes toward people addicted to prescription pain medication    







Agree that people who are addicted to prescription pain medication are irresponsible 0.16 
(-0.17, 0.48) 
-0.19 
 (-0.53, 0.15) 
0.04 





Agree that employers should be allowed to deny employment to persons addicted to 













Perceptions of treatment effectiveness    














Policy support    
Punitive policies    
Prosecute pregnant women who are addicted to prescription pain medication on criminal 






Require health care providers to report women who have abused prescription pain medication 






Public health oriented policies    
Pass immunity laws to protect pregnant women addicted to prescription pain medication from 
















Expand Medicaid health insurance benefits for low income families to cover treatment for 






Require individuals enrolled in Medicaid health insurance that are suspected of abusing 



























Asterisks(*p-value<0.05 **p-value<0.01) indicate statistically significant coefficients, comparing the experimental group to the control group, which is the 
reference category.   
a 
Wald post-estimation tests were conducted to test whether the coefficient for the low SES base narrative group was significantly different from the coefficient 
for the high SES base narrative group.  
Ordered logistic regression models were used to produce the coefficients, which are proportional log odds ratios. Models are weighted to adjust for the survey 







Table 3: Effects of narratives portraying a low SES pregnant woman facing barriers to treatment on public attitudes, compared to the low 
SES base narrative with no depiction of barriers to treatment (N=553), 2014  
 
Coefficient (95% CI) 
Low SES narrative with barriers to 
treatment vs. low SES base narrative 
Attitudes toward population  
People who are addicted to prescription pain medication are to blame for their drug addiction. 
-0.07 
(-0.38, 0.25) 
People who are addicted to prescription pain medication are irresponsible. 
-0.15 
(-0.48, 0.18) 




Employers should be allowed to deny employment to persons addicted to prescription pain medication. 
-0.39* 
(-0.70, -0.07) 
Landlords should be allowed to deny housing to persons addicted to prescription pain medication. 
-0.17 
(-0.49, 0.16) 
Perceptions of treatment effectiveness  








Policy support  
Punitive policies  




Require health care providers to report women who have abused prescription pain medication during 
pregnancy to state authorities, such as child welfare agencies.  
-0.42* 
(-0.74, -0.10) 
Public health oriented policies  
Pass immunity laws to protect pregnant women addicted to prescription pain medication from being 
charged with drug crimes if they seek treatment for their addiction.  
-0.02 
(-0.34, 0.29) 








pain medication addiction. (0.00, 0.62) 
Require individuals enrolled in Medicaid health insurance that are suspected of abusing prescription 












Asterisks(*p-value<0.05 **p-value<0.01) indicate statistically significant coefficients, comparing participants exposed to the narrative portraying barriers to 
treatment to participants exposed to the low SES base narrative that does not mention treatment (reference category). Ordered logistic regression models were 
used to produce the coefficients, which are proportional log odds ratios. Models are weighted to adjust for the survey sampling design; the weights enable 










Table 4: Effects of narratives portraying a high SES and low SES pregnant woman with successful treatment on public attitudes, 
compared to the high and low SES base narratives with no mention of treatment, 2014 
  
Coefficient  (95% CI) 
Low SES narrative 
with successful 
treatment vs. low 
SES base narrative 
 
N=545 
High SES narrative 
with successful 
treatment vs. high 
SES base narrative 
 
N=543 
Attitudes toward people addicted to prescription pain medication   








Unwilling to work closely with a person with an addiction to prescription pain medication 

















Perceptions of treatment effectiveness   
Most people addicted to prescription pain medication can, with treatment, get well and return 











Policy support   
Punitive policies   






Require health care providers to report women who have abused prescription pain medication 





Public health oriented policies   
Pass immunity laws to protect pregnant women addicted to prescription pain medication from 














Expand Medicaid health insurance benefits for low income families to cover treatment for 





Require individuals enrolled in Medicaid health insurance that are suspected of abusing 






















Asterisks(*p-value<0.05 **p-value<0.01) indicate statistically significant coefficients, comparing the successful treatment narrative groups to the background 
narrative groups, which are the reference categories. For instance, the high SES successful treatment group is compared to the high SES base narrative group 
(reference category) while the low SES successful treatment group is compared to the low SES base narrative group (reference category). Ordered logistic 
regression models were used to produce the coefficients, which are proportional log odds ratios. Models are weighted to adjust for the survey sampling design; 










Persons with addiction to opioids (i.e., heroin and opioid analgesic medications) and 
other substances experience significantly higher rates of physical and mental health disorders than 
the general population.
1–3
 In addition to increased susceptibility to communicable diseases such as 
HIV/AIDS and hepatitis C, those with substance use disorders are at elevated risk of lung disease, 
cardiovascular disease, liver cirrhosis, cancer, and serious mental illness (SMI).
3,4
 Premature 
mortality in this population often results from complications related to somatic conditions rather 
than drug overdose.
5–7
 Compared to those with just a chronic physical condition, Medicaid 
enrollees who also have co-occurring substance use and mental health disorders accrue health 
care costs that are two-three times higher.
8
  
Research suggests that integrating somatic and behavioral health care services for this 
population can improve patient outcomes and reduce emergency department utilization.
9–13
 Yet 
the financing and healthcare delivery infrastructure for substance use, mental illness, and somatic 
conditions have long been segregated.
14
 Historically, this separation was due in part to lack of 
parity in health insurance coverage of behavioral health services. Recent policy changes including 
the 2008 Mental Health Parity and Addiction Equity Act and the 2010 Affordable Care Act 
(ACA) have required equitable insurance benefits for addiction treatment.
15
 In addition, the ACA 
has established new mechanisms to promote the integration of behavioral and somatic health care, 
including the Medicaid health home state option.
16
  
Under Section 2703 of the ACA, states can design and implement health homes to 
improve quality of care for Medicaid beneficiaries with chronic health conditions.
17




90% federal matching for the first eight quarters that a patient is enrolled in a health home.
17
 By 
the end of 2014, 17 states had obtained approval from the Centers for Medicare and Medicaid 
Services (CMS) to establish health homes for targeted groups of Medicaid enrollees.
18
 The 
Medicaid health home option provides states with considerable flexibility in defining eligibility 
criteria for patients and providers.
19
 As of April 2015, Maryland, Rhode Island, and Vermont 




Maryland’s health home program became effective in October 2013.
20
 It targets enrollees 
with a diagnosed opioid use disorder engaged in medication-assisted treatment (MAT) at licensed 
opioid treatment programs (OTPs) and enrollees with serious mental illnesses (SMI) or serious 
emotional disturbances (SED) receiving services at psychiatric rehabilitation programs (PRPs) or 
through mobile treatment services (MTS) providers. To be eligible for health home participation, 
opioid dependent patients also must be at risk of developing another chronic condition based on 
prior or current use of tobacco, alcohol or other substances.
19
 Given that co-occurring substance 
use is widespread among this population (for example, estimates suggest that between 73-94 
percent of methadone maintained patients use tobacco products
21
), this eligibility criteria 
encompasses most OTP patients.  
Preliminary research on the Medicaid health homes has included descriptive studies of 
state variation in structuring their health home demonstrations, as well as evaluations of early 
effects on quality of care, clinical outcomes, hospitalizations, and costs.
16,19,20,22,23
 Qualitative 
research on Medicaid health homes is limited and minimal research has examined the 
implementation of health homes in OTPs.
20
 
At the time of this study, there were 69 OTP provider sites in Maryland,
24
 all of which 
were eligible to become health homes. OTPs provide methadone treatment (dispensing on-site 
daily doses and take-home doses for more stable patients), medical examinations, counseling and 
behavioral therapies, and routine drug screening tests.
25,26




services including: mental health services, testing for hepatitis C and HIV, recovery groups, and 
on-site or referral to educational and employment resources.
26
 According to data from the 
National Survey of Substance Abuse Treatment Services (NSSATS), 15,437 Maryland patients 
were receiving methadone maintenance therapy (MMT) in 2011.
27
 Although buprenorphine, 
another medication used to treat opioid addiction, is primarily offered in office-based settings, 
OTPs are increasingly providing this medication as well.
28
 Among the over 2,400 Maryland 
patients maintained on buprenorphine in 2011, 468 were receiving treatment in OTPs.
29
  
In order to become a health home in Maryland, OTPs must first complete an application 
and obtain approval from Maryland’s Department of Health and Mental Hygiene’s (DHMH) 
Medicaid and Behavioral Health Administration (BHA) agencies. Health homes have to maintain 
certain staffing levels for the following positions: health home director, nurse care manager, and 
medical consultant (see Appendix 3.1 for additional information).
30
 In addition, health homes are 
required to obtain health home accreditation from the Commission on Accreditation of 
Rehabilitation Facilities (CARF) or the Joint Commission within 18 months of obtaining state 
approval. Maryland health homes use an electronic reporting system, eMedicaid, to verify patient 
eligibility and to submit monthly reports on the health home services they have provided. 
Providers receive an initial intake reimbursement of $98.87 for each new enrollee as well as a per 
member per month (PMPM) rate of $98.87 for providing at least 2 health home services monthly 
for each patient. Health home services fall into the following categories: comprehensive care 
management; care coordination; health promotion; comprehensive transitional care; individual 
and family support; and referral to community and social support services.  
Adoption of the health home among OTPs has been low. As of April 2015, over 90 
percent of the 75 health homes approved to-date were in PRPs. Virtually all of the PRPs with 
sufficiently large patient populations are implementing health homes. In contrast, of the 69 OTPs 
in the state, less than 10 OTPs had applied to become health homes, and of these, only five in 




Maryland OTP sites). As of February 2015, two of the approved health homes had discontinued 
their programs, leaving three OTPs actively providing health home services. 
Health services interventions that researchers find to be effective in one context often fail 
to translate to other settings.
31,32
 Factors that can impede translation of interventions include 
differences in provider setting and patient population. OTPs serve a vulnerable patient population 
with unique health and social services needs. Implementing new models of care within this 
setting may involve atypical challenges and solutions. Implementation science involves 
examining the processes related to dissemination of research findings and their adoption and 
implementation in a variety of contexts.
33
 This study examined the adoption and implementation 
of Medicaid health homes in Maryland OTPs through qualitative analysis of data collected 
through in-depth interviews with leaders in OTPs in Maryland and state officials. Specifically, 
this research sought to identify and explain: the facilitators of successful implementation among 
OTP health homes; challenges faced by OTP health homes during the implementation process; 




We conducted semi-structured interviews with key informants at: (1) OTP health homes; 
(2) OTPs not implementing health homes; and (3) in Maryland state government agencies 
charged with overseeing OTP health home implementation. An initial list of potential 
interviewees was developed using SAMHSA’s online OTP directory
24
 and Maryland state 
government resources on the health home demonstration. We purposefully selected key 
informants at OTP health homes based on their leadership role and level of involvement with the 
health home. We used stratified purposive sampling to identify directors at non-participating 
OTPs from diverse geographic settings (rural, urban, and suburban) and with varied operational 




with Maryland state government officials, we identified key informants at Maryland’s Medicaid 
and Behavioral Health Agencies who had been involved in the planning, implementation or 
evaluation of the health home demonstration. Study participants were recruited by email and by 
telephone. Interview recruitment continued until data saturation had been reached at 17 
interviews. 
Separate, semi-structured interview guides were developed for the three types of 
interviewees – OTP health home providers, non-participating OTPs, and state agency officials 
(see Appendix 3.2). Interviews with OTP health home providers included questions about their 
motivation to become a health home, the implementation process, including its facilitators, 
challenges, and lessons learned, and perceived effects on their organization to-date. Interviews 
with OTP providers that had not implemented a health home focused on what they knew about 
the health home, whether they had considered adopting, perceived barriers to adoption, future 
plans, and general attitudes toward the health home demonstration. Interviews with government 
officials concentrated on the design of the health home demonstration, its roll-out and 
implementation, the evaluation of the health home, and concurrent policy changes related to 
OTPs and the state’s recent integration of its substance use and mental health administrative 
agencies.  
Interviews were conducted between February and April 2015 and took place mainly in-
person, with two conducted by phone. With participant consent, all interviews were audio-
recorded and transcribed. This study was determined to be not human subjects research by the 
Johns Hopkins School of Public Health Institutional Review Board. 
 
Analysis 
We used a hybrid deductive and inductive coding approach to analyze the interview data. 
Based on prior literature on the implementation of medical homes
34,35
 and an initial reading of the 




coding, new inductive codes were developed and applied as part of an iterative coding process. 
NVivo® qualitative data analysis software was used to code all transcripts. Transcripts from 
interviews with the three sets of participants (health home provider; OTP not implementing a 
health home; and state government official) were coded together. The codes generated for each 
concept emerging from the data were then collapsed into a smaller number of more broadly-
defined groups in order to identify the major themes. 
Results 
 
In total, 17 in-depth interviews were conducted with 19 participants. These included: 6 
interviews with OTP health home leadership staff; 8 interviews with non-participating OTP 
administrators who oversaw 15 OTPs in the state; and 3 interviews with Maryland officials from 
the Department of Health and Mental Hygiene (DHMH). Interviews ranged in length from 38 
minutes to 1 hour and 39 minutes (mean interview duration = 55 minutes).  
 
Health homes 
Among the three active OTP health homes, two were early adopters and had been in 
operation since late 2013. At the time of interviews, the third OTP had just opened and begun 
rolling out its health home simultaneously with its other services; it also was in the process of 
establishing on-site primary care and behavioral health services. Given that this OTP was at the 
beginning of its implementation process, this section focuses mainly on the experiences of the 
two OTP health homes that had been in operation for over a year at the time of the interviews.  
  
Motivation to implement a health home 
Although they did conduct internal analyses to determine financial feasibility, the OTPs 
implementing health homes generally described their decisions as “no-brainers” because the 




the three health homes had ongoing or future plans to offer primary care services on-site. Thus, 
the health home aligned with their organizational goals. The two more established OTPs felt that 
they were providing some of the health home services already, such as referrals and care 
coordination with other medical providers. They perceived the health home as a way to formalize 
and build upon these services, and obtain compensation for work their staff were already doing. 
As non-profit organizations, the OTPs noted that they operated on limited budgets, so the added 
PMPM reimbursements for health home patients enabled them to continue improving their 
services while removing some of the burden on existing staff who were stretched thin. One of the 
interviewees observed that, given changes in the health care system such as the Medicaid 
expansion, implementing a health home offered the opportunity to help a vulnerable population 
navigate these changes more easily.  
 
Facilitators to successful health home implementation 
Table 1 displays illustrative quotations from the interviews that exemplify themes that 
emerged from the interviews related to facilitators of the implementation. The major themes 
included: health home staff interpersonal skills; gaining patient trust and respect; obtaining buy-in 
from the clinical director and counselors; engaging health home patients; making the health home 
space accessible and inviting to patients; and collaborating and sharing information with the other 
OTP health homes. 
 
Interpersonal skills of health home staff 
While the OTPs identified their health home staff as critical to the smooth 
implementation of the health home, they took different approaches to filling these positions. One 
of the OTPs hired a new nurse to fill the health home director and nurse care manager positions 
simultaneously during the initial stage of implementation and later hired a FTE nurse care 




the success of the implementation, speculating that “I think we would’ve struggled more with it 
really” without finding the “right person” to fill the health home director and nurse care manager 
positions. In contrast, the other OTP was able to rely on existing nurses on-staff to fill the health 
home positions. This OTP acknowledged that their organization already offers a number of 
supplementary services so their existing staffing structure might be unique among OTPs. At this 
OTP, interviewees cited the nurses’ existing familiarity with patients, such as the fact that the 
nurses knew most patients already on a first-name basis, as a facilitator. “We weren’t a mystery to 
people. People were comfortable with us already…I think that was a plus for us--we weren’t 
starting from scratch.” 
In addition, the staff took different approaches to care coordination and comprehensive 
care management. At one of the OTP health homes, the nurse care manager frequently called 
providers on behalf of patients to help them set up appointments and occasionally joined patients 
at their appointments with medical providers. In contrast, the other OTP expressed a different 
philosophy in which they wanted to “empower patients to become autonomous,” and did not 
accompany patients on visits to other clinicians. Similarly, one health home scheduled internal 
appointments with its patients whereas the other health home typically did not, instead asking 
patients to check in with them and tracking down those who had not interacted with the health 
home that month. In terms of other staffing decisions, OTPs had to use existing staff to support 
administrative efforts, such as scanning medical records collected from other providers into the 
OTPs’ health IT systems.  
 
Gaining patient trust  
The health homes identified the development of patient trust as critical to their 
implementation success. The OTPs noted that trust is particularly important for this patient 
population due to long-standing and widespread mistrust of medical professionals. Regarding 




patients say like ‘I’m not going to take that [medication], because they’re [the doctor] 
experimenting on me.’ And especially I’ve noticed this with patients with hypertension.” In order 
to fulfill the objective of the health home, which is to integrate behavioral health and somatic 
care, health home nurses had to earn patients’ trust as well as address their mistrust of other 
medical professionals. Health home nurses leveraged counselors’ long-standing relationships with 
patients to encourage use of prescribed medication, for instance. In addition, one of the OTPs 
undertook informal and formal efforts to educate other medical professionals about opioid 
addiction and methadone treatment and reduce stigma. Informal efforts included conversations 
with their patients’ medical providers. More formal efforts included bringing in medical and 
nursing students from local universities to do rotations at the OTP.  
 
Patient engagement 
In order to generate sufficient revenue to support the health home, the OTP needed to bill 
for as many of its enrollees as possible each month; this required providing at least two services a 
month to receive PMPM for each enrollee. Critical to this objective was engaging patients. While 
fostering trust in patients was somewhat intangible, often described by the interviewees as part of 
their organizational culture and approach to patient care, the interviewees thought that their 
philosophies were transferrable to other OTP settings. More tangible were efforts to engage 
patients in the health home. One OTP set up a “fast track” system in which patients seeing a nurse 
for a health home visit could move to the front of the methadone dosing line. The health home 
nurse thought that this perk made the patients feel special. Another OTP prepared newsletters on 
particular health topics, which contained quizzes about its content. Patients who completed the 
quiz were entered in raffles to win gift cards to a nearby grocery store. They also occasionally 






Accessible and inviting physical space 
One perceived key to engaging patients was the location of the health home within the 
OTP. Both OTPs emphasized the importance of the health home being an accessible and inviting 
space for patients. One OTP strategically located the health home on the first floor “where the 
traffic is heaviest to…capture as many people as we can for their monthly services.” This OTP 
noted that the first-floor space was valuable real estate within the organization. Similarly, the 
other health home operated within a newly remodeled space that they thought the patients found 
to be attractive and that was convenient to the counseling offices, intensive outpatient group 
areas, and other important components of the organization. 
 
Buy-in from clinical directors and counselors 
Given that the health home is intended to be a part of the OTP, rather than a supplement, 
health home staff noted that achieving the buy-in of the clinical directors and counseling staff was 
critical. Involving counseling staff in the health home was important not only to ensure that the 
health home was a part of the broader OTP but also to address the logistical difficulty in 
providing two health home services per month per patient for over one hundred patients. 
Counselors at these OTPs also helped to recruit new health home enrollees. The OTPs 
experimented with different approaches to involving the counselors in providing health home 
services and documenting qualifying services they had already been providing prior to the 
implementation. Both established health homes tried to have counselors deliver some of the 
health promotion services and provided counselors with materials (i.e., documents summarizing 
information on particular health home topics, videos on smoking cessation) to discuss with their 
patients. 
 




The health homes worked collegially with one another, sharing policies and procedures 
they had developed and exchanging ideas as they began to prepare for the CARF accreditation 
process. The several OTPs originally approved to become health homes, including the two that 
discontinued their health homes, initially met regularly and formed a health home learning 
collaborative for OTPs. However, when two of the OTPs discontinued their health homes, the 
learning collaborative disbanded. The OTP health homes have shared their experiences at the 
Maryland Association for the Treatment of Opioid Dependence (MATOD) meetings, and been in 
contact with other OTPs interested in pursuing a health home.  
As the health home demonstration rolled out, both the OTPs and state officials indicated 
that they were able to resolve issues of confusion collaboratively. The state adjusted policies that 
lacked clarity or did not work well in practice. One state interviewee noted that “it’s not like [the 
health home demonstration] launched and then it’s been a static program…the providers that have 




The OTPs faced several challenges during the implementation process, some of which 
they had already addressed at the time of the interviews. These included: their pioneer status as 
early adopters; staffing; incorporating the health home into the OTP; balancing time devoted to 
high-need versus healthier patients; health IT issues; billing; dealing with non-eligible patients; 
and the delivery of particular categories of health home services. Table 1 displays illustrative 
quotations from the interviews that provide examples of these challenges. 
 
Pioneer status 
As early adopters, these health homes felt that their pioneer status posed a challenge, as 




Maryland identified Missouri as its model for the health home demonstration, Missouri did not 
implement health homes in OTPs. In addition, the pilot health home in Maryland was 
implemented in a psychiatric rehabilitation program and targeted Medicaid enrollees with SMI. 
While the OTP health homes felt that they benefitted from the knowledge and experiences of the 
pilot site, given the differences in patient population, types of services provided, and OTP staffing 
ratios (1 counselor for every 50 patients at OTPs versus 1 staff person for every 10 patients at 
PRPs), much of that experience did not translate to the OTP setting. The current health homes 
will be the first OTPs in Maryland to go through the CARF health home accreditation process. 
CARF accreditation was a source of anxiety among the health home interviewees because they 
felt that there were so many unknowns and no models from which to learn. 
 
Staffing 
While citing the interpersonal and professional skills of the staff as facilitators of the 
implementation, the health homes also reported some minor challenges related to staffing 
decisions. The new health home nurses had to develop relationships with patients from scratch 
while the OTP that used existing staff felt that these patient relationships were well-established. 
However, the OTP that used existing staff had to make a concerted effort to protect the time of 
the health home nurses, who were occasionally recruited for other tasks, such as assisting with 
methadone dosing when the line became too long. In addition, the health homes felt that the 
staffing ratios in the health home regulations were unrealistic. As a result, they have had to rely 
more than originally anticipated on assistance from counselors in delivering two health home 
services monthly. 
 
Incorporating the health home into the OTP 
Changing the organizational culture so that the OTP staff view the health home as part of 




still a work-in-progress. One of the health homes felt that while they have largely obtained 
sufficient buy-in, they are still struggling to get the counselors to document the health home 
services that they provide. In addition, they are trying to broaden the idea of behavior change as 
not just substance use related but applicable to somatic conditions with behavioral components, 
such as diabetes, hypertension, and asthma. One of the health homes suggested that their 
counselors might play larger roles in assisting patients with chronic illnesses by using some of the 
same behavior change techniques they apply to patients’ substance use to helping patients make 
adjustments to their diet, exercise habits and other aspects of their lifestyle relevant to somatic 
conditions. 
One way to involve counseling staff and further incorporate the health home into the OTP 
was through the development of integrated treatment plans that include patients’ substance use 
treatment and somatic health goals. The health homes were at different stages in terms of 
implementing integrated treatment plans. One of the health homes added the patients’ health 
goals to the existing substance use treatment plans with the goal to promote shared responsibility 
(with the counselors) for the patients achieving their health goals. The other health home has had 
regular meetings for health home patients in which the health home nurses, medical director, 
clinical director, and other key staff discussed enrollees’ treatment plans together to ensure a 
more collaborative approach to addressing these patients’ needs. 
 
Balancing time devoted to high-need and healthier patients 
Balancing the time the health homes devote to high-need patients with serious medical, 
psychiatric, and psychosocial problems versus healthier patients has been an ongoing challenge. 
The difficulties have been exacerbated by the need to bill for enough patients each month to 
support the health home. The frequency with which patients see health home nurses varies. In 
addition, both health homes are in OTPs that have patient populations that are aging and have 





Health information technology 
OTPs face unique challenges with respect to health IT due to requirements specific to the 
methadone treatment setting. The health homes felt that their internal health IT software lacks the 
features that would be needed if they were to integrate primary care services on-site in the future. 
In addition, the health homes’ experience with eMedicaid has been mixed. The providers like the 
eligibility verification feature, noting that they generally have had few payment denials because 
they are able to confirm eligibility at intake. Reimbursement turnaround has been timely, which is 
hugely important to organizations operating on tight budgets. The reporting features in eMedicaid 
were not perceived as supporting the type of population health management the state encourages, 
although it is not clear that the eMedicaid system was intended to be used this way. Many of the 
PRPs use ProAct, an IT system adopted initially by Missouri health homes, which has more 
sophisticated population health management capabilities. However, the OTPs have not adopted 
this system due in part to limited funding and the unique health IT needs of OTPs. Interviewees 
noted that the existing software platforms suitable for OTPs (i.e., include a methadone dosing 
system and fulfill DEA requirements for inventory and accounting) do not have electronic health 
record (EHR) capabilities that would support meaningful use.  
The health homes have customized templates in their existing software programs to 
create “health home notes” to document provision of services. Health home staff, as well as other 
OTP staff like counselors, have access to and contribute to these health home notes. At the end of 
each month, at one of the OTPs, the health home nurses have been running reports on all health 
home notes entered in the health IT system and entering this information into the eMedicaid 
system for billing purposes. The other OTP has asked counselors to email the health home 
director whenever they provide a health home service but are transitioning to greater reliance on 
the electronic health home notes. The health homes also have used their health IT system to 




reminders for an appointment with an external provider. However, the software these OTPs 
currently use, while appropriate for the OTP setting, would be insufficient in a facility in which 
primary or somatic health services are provided on-site. Thus, as OTP health homes expand the 
types of services they provide, a significant challenge will be the lack of health IT options 
available to them that offer the necessary features for delivering methadone maintenance therapy 
and medical services.  
 
Billing 
One of the challenges the OTPs faced early on the implementation process was figuring 
out how to bill for services that the counselors had already been providing. OTPs receive a 
bundled rate for providing standard OTP services such as daily methadone dosing, monthly 
counseling sessions, and drug screenings. However, prior to the health home implementation, 
counselors at both OTPs had often provided additional services and contacted local doctors or 
social services agencies on behalf of patients. After discussing with state officials, the OTPs 
received guidance to bill for a qualifying health home service even if it was provided by a 
counselor during a counseling session as long as the service was not directly related to substance 
use treatment. While the logistics are still being addressed internally by the health homes, 
clarification from the state has helped to reduce confusion. 
 
Ineligible patients 
The inability to enroll non-qualifying OTP patients also has been a source of frustration 
for the health homes because they feel that these patients would benefit tremendously, 
particularly non-qualifying Medicare patients. There was no consensus among interviewees about 
whether the health home affected patients who were not enrolled positively or negatively. The 
OTPs have chosen not to restrict access to group health home activities, such as nutrition classes 





Delivery of particular types of health home services 
The health homes have struggled to deliver particular types of health home services, 
particularly the provision of family support. For the OTPs, involving family members has always 
been a challenge due to several factors: (1) patients’ relationships may have been damaged with 
family members due to their substance use; (2) patients’ family members may be actively using 
substances; and (3) family members may be skeptical about methadone treatment.  
 
 Perceived effects of the health home on the OTP and its patients 
 Overall, these OTPs were positive about the health home and felt that it had benefitted 
both OTP staff and the patients. One of the OTPs felt that the implementation of the health home 
had increased job satisfaction, particularly among the clinical staff. One of the interviewees said 
“I really can’t imagine working here without it...I see it in the patients here. I see it in the morale 
of our whole clinical team.” In addition, both health homes felt that it has had a beneficial effect 
on the quality of services they are providing and on patient health. Interviewees were skeptical 
about the extent to which the state would be able to detect a measurable impact on costs to-date, 
noting that some patients were using more care as they received services related to health issues 
that previously had been neglected. For instance, one interviewee noted “I'm sure our people are 
maybe dusting off their cards and getting health care for the first time.” At both of the established 
health homes, there was a sense that health home enrollees were experiencing improvements in 
the severity of their substance use disorders (typically, non-opioid substances like cocaine, 
marijuana or other prescription drugs). Both health homes hypothesized a similar pathway 
through which persons who were not stable in their addiction at the start of the health home have 
begun to pay greater attention to their overall health and wellbeing, which has then led to 
reductions in other substance use. Finally, both OTPs felt that the health home has established 




of specific success stories in which patients made important gains, or had serious medical issues 
addressed (e.g., attainment of prosthetics and dentures) due to health home intervention.  
 
Future plans 
The health homes shared a number of future plans to improve upon the services they are 
offering. These included: organizing monthly in-service trainings for counselors on specific 
health topics to strengthen their ability to provide health promotion and education services; 
identifying medical provider partners more systematically and providing information on opioid 
dependence and MAT; engaging health professional students from local universities as a means 
of reducing stigma among clinicians; and refining unified treatment plans for clients. In addition, 
two of the three OTPs had future plans to provide primary care services on-site.  
 
Barriers to adoption among OTPs that have not implemented health homes 
State officials identified adoption among the OTPs as one of the main challenges with 
respect to the Medicaid health home demonstration. If findings from an ongoing intra-state 
evaluation
1
 indicate that the health homes are having a positive impact on quality, patient health 
or hospitalizations, the state will ramp up efforts to increase participation among OTPs. All of the 
OTP directors interviewed for this study felt that the OTP was an appropriate setting for a health 
home and that, in concept, the health home was a good idea. Table 2 displays the key themes 
identified through interviews with directors at OTPs that were not adopting the health home. 
These included: hesitancy to adopt a new program in the midst of other state policy changes; 
financial risk; staffing requirements; too few eligible patients; insufficient physical space in the 
OTP; the requirement of a separate health home accreditation; confusion about billing 
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procedures, the logistics of integrating somatic care, or the application; organizational culture and 
leadership; and uncertainty about the permanency of the health home program. 
 
Simultaneous changes in the regulatory and financing environment 
At the time that the health home demonstration rolled out in Maryland in 2013, OTPs 
were facing other major changes in the regulatory and financing environment. Some OTPs in 
Maryland had been receiving grant funding under the Substance Abuse Prevention and Treatment 
(SAPT) block grant administered by state and local governmental entities for uninsured patients. 
However, with the expansion of insurance under the ACA, particularly through Medicaid, 
funding for OTP services has been shifted as more OTP patients obtain insurance coverage. One 
OTP director felt that this was, in some respects, a budget cut because the staff required for 
billing purposes is an added strain on OTPs’ tight operating budgets. Numerous OTPs expressed 
that, in this time of change, they have been operating in “survival mode.” As Maryland’s previous 
Medicaid expansion, Primary Adult Care (PAC), wound down and the ACA Medicaid expansion 
ramped up, OTPs reported that they had felt a sense of instability that reduced their willingness to 
undergo organizational changes. In addition, in 2014, the state announced that a new 
administrative services organization (ASO), ValueOptions, would handle Medicaid billing for 
mental health and substance use treatment services. Previously, OTPs submitted claims to the 
various MCOs in the state. The transition to the ASO occurred in early 2015. At the time of the 
interviews, most, albeit not all, providers were fairly positive about the Value Options transition. 
However, the lead-up nevertheless was described as another source of uncertainty. Finally, in 
addition to these changes in the financing environment, both the state and Baltimore City 
integrated administratively their mental health and substance use agencies.  
 




Financial risk and interrelated concerns about staffing requirements and having sufficient 
numbers of eligible patients also were mentioned by a number of the OTP directors as factors 
contributing to their decision not to apply to become health homes. There was uncertainty about 
whether the health home reimbursement rates would make up for initial investments (i.e., start-up 
costs), such as hiring a RN to fill the health home director and nurse care manager roles. OTPs 
with smaller patient populations (<125 patients) did not feel that it was financially viable to hire 
an additional nurse. In addition, while no interviewees indicated that their organization did not 
implement a health home due to concerns about profitability, several OTPs suggested that some 
of the for-profit OTPs already offer limited services and might be disinclined to adopt a health 
home due to uncertain return on investment (ROI). In addition, some OTPs in the state are owned 
by out-of-state companies that operate clinics in multiple states. The extent to which ROI 
calculations played a role in these companies’ decision-making surrounding the health home is 
unknown. In addition to issues related to financial viability and staffing requirements, some OTPs 
also did not feel that they had the physical space to house a nurse’s office and/or exam room to 
support health home activities. One OTP director noted: “every corner of my building is filled 
with a human being.”  
 
Separate accreditation requirement 
A number of OTPs identified the requirement of a separate accreditation as a health home 
as a significant barrier to adoption. Obtaining health home accreditation is expensive (e.g., CARF 
health home accreditation is $7,000), particularly for small OTPs. In addition, the time and 
energy required to prepare for the accreditation process is substantial. For OTPs that had just been 
re-accredited for a three-year period, the idea of going through the process again to obtain the 
separate health home accreditation was daunting.  
 




There were several conceptual areas of confusion for the OTPs surrounding billing and 
the practical matter of integrating the health home into the OTP. Several OTPs expressed 
confusion about how to differentiate services they already provide (i.e., referrals to other medical 
providers) from health home services. Some interviewees expressed discomfort about the 
possibility of accidental duplicative billing and Medicaid fraud. However, as noted in the 
previous section, the state and existing health homes have addressed this concern already by 
specifying that as long as the service is not directly related to substance use treatment, OTPs can 
still bill for the service even if delivered within the confines of a counseling session. Therefore, 
OTPs may benefit from the learning experience of the early adopters. Similar to the billing issue 
was a lack of understanding from several of the OTPs about how this integration of the health 
home and OTP would take place in practice. The OTPs that have not adopted the health home 
realized that this type of change would transform their organizations. However, undergoing a 
practice transformation felt overwhelming to some OTP directors. One of the OTPs felt that the 
application to obtain health home approval from the state was confusing, particularly the 
standards section, but this barrier was not mentioned by other OTPs perhaps because few other 
organizations had considered applying. 
 
Organizational culture and leadership 
Interviewees cited variability among OTPs in terms of organizational culture. OTPs vary 
in the quality and scope of services that they provide, therapeutic approach to care, and 
willingness to try new approaches. Interviewees distinguished between OTPs that provide the 
minimal services and meet the minimum staffing levels required by law and OTPs that offer 
additional services and view themselves as having a patient-centered approach. Several 
interviewees identified for-profit OTPs as less likely to fit in the latter category. However, among 




provide additional services due to profit motivations. In fact, the few for-profit OTPs we 
interviewed were providing more extensive services than required. 
Many of the OTPs expressed interest in and enthusiasm for the health home. Given that a 
number of the major state-level changes have been implemented at this point, several OTPs 
indicated that they were now considering applying to become health homes. One OTP was 
discontinuing an existing program and was considering the reinvestment of those resources in a 




Many of the facilitators and challenges related to the health home implementation among 
Maryland OTPs corresponded with findings in other research on implementations of new models 
to integrate primary care and behavioral health; these included the importance of staff and 
physical space, developing integrated treatment plans and protocols, and issues related to billing 
procedures.
34–36
 A number of the facilitators of the health home implementation fell within the 
category of “soft practices,” defined by Hoff as “relational in nature” and deriving “from existing 
practice social structure and everyday interactions with staff and patients.”
35
 While the ways in 
which these soft practices developed at the two established health homes were distinct, the 
importance of the relationships health home staff built with their patients and with the OTP 
counselors were viewed as critically important to the success of the health home implementation.  
Several aspects of the implementation process might be unique to the OTP setting, 
particularly the relationships that health home staff had to develop with their patients and other 
medical providers in order for the health home to function well. All interviewees noted high 
levels of patient mistrust of medical professionals and institutions. Mistrust is associated with 
lower utilization of health care services.
37
 OTPs may be uniquely positioned to help patients 




their patients (nearly every day) and the length of these relationships (often over the course of 
many years). Health homes also are well-positioned to play an informal role in educating other 
medical professionals about opioid use disorder and methadone treatment,
38
 a role that might 
reduce stigma as well as improve patients’ trust in and comfort with other clinicians.   
One theme that emerged from these interviews was that the OTP patient population is 
aging (although there may be a future influx, given rising rates of prescription opioid and heroin 
addiction
39
). Research has documented increased rates of SMI, somatic chronic illness, and poor 
physical functioning among aging methadone-maintained patients.
1,2,40
 The OTP health homes 
have observed an increase in the complexity of medical problems among their OTP patients as 
the health home has been implemented, likely due to increased detection. If the state decides to 
extend the health home program depending on the evaluation findings, efforts to expand adoption 
among non-participating OTPs will be important, given the role these providers play in serving an 
aging population with serious chronic medical conditions.  
The two established OTPs implementing health homes were considered, both by the state 
and by other OTPs, to be leaders in the OTP Maryland community. According to theory on the 
dissemination of  innovations, these providers might be categorized either as “innovators” or 
“early adopters.”
41
 However, there are a number of other OTPs in Maryland that display similar 
organizational philosophies and levels of willingness to provide new services in order to improve 
quality of care and patient experiences. Many of the barriers to adoption identified by OTPs were 
related to feelings of instability and uncertainty about recent policy changes that have now been 
implemented, as well as unresolved questions about the billing process and how integration 
would function in practice. Many of these issues have been resolved. For instance, concern about 
duplicative billing should no longer hold providers back from participating given clarification 
from the state. The positive experiences of the early adopters of the health home also may 
encourage other providers to participate. Once the health homes have gone through the CARF 




The degree to which the for-profit status of an OTP affects health home adoption is 
uncertain. Interviewees frequently cited this as a potential hindrance to adoption for other OTPs 
but not for their own organization. A subset of OTPs are owned by out-of-state companies; this 
may complicate state efforts to promote the health home, given that decisions about service 
expansions are made by company executives located in other states rather than the local OTP 
directors. If the state hopes to achieve broad participation among OTPs, it may need to rethink 
how it targets recruitment given that current promotional efforts may not reach these key 
decision-makers. However, given that the majority of OTPs are locally owned, out-of-state 
ownership may not pose a significant barrier to recruitment. Research suggests that OTP 
ownership has implications for service expansion.
42
 An analysis of NSSATS data indicates that 
for-profit OTPs are significantly less likely than non-profit and public (i.e., government-run) 
OTPs to provide additional services beyond those required by law.
42
 However, the third OTP 
health home that just recently opened is for-profit. This OTP’s implementation experience will be 
especially informative to other for-profit OTPs considering adoption.  
 
Limitations 
Given the use of stratified purposive sampling, participants in this study may not be 
representative of the views of leadership of all OTPs in Maryland. The findings may be somewhat 
limited in their transferability to other Maryland OTPs and to other states considering the 
implementation of health homes among OTPs. Although Maryland is currently experiencing an 
opioid overdose epidemic that includes rural and suburban residents, nearly half of the state’s 
OTPs are in Baltimore City. However, it is also true nationwide that OTPs are concentrated in 
urban areas.
43
 It is possible that Baltimore is unique in the extent to which OTPs have formed 
collegial relationships in which information-sharing is welcomed and encouraged. This 
environment may facilitate a smoother implementation of the health homes if other OTPs choose 




Future research should examine the way in which the implementation is perceived by substance 
use treatment staff that has little to no prior experience with medical models of care. 
 
Conclusion 
Only three OTPs are implementing health homes in Maryland. Two have been in 
operation for over a year and cite the importance of staffing and interpersonal relationships, trust 
and patient engagement, and physical space as important facilitators. Poor rates of adoption 
among OTPs may have been related in part to the timing of the roll-out of the health home 
demonstration in the midst of other state policy changes. Although the existing OTP health homes 
have been eager to share their experiences at professional association meetings, the state may be 
able to leverage these leaders further to promote more widespread adoption of the health home in 
the OTP setting. Despite the challenges faced in Maryland, OTPs present a unique opportunity for 
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Table 1. Facilitators of implementation among OTP health homes 
Facilitators 
Staff inter-personal skills 
 
“I think if [finding and hiring the health home director] had not happened, I think we would have struggled more because it was so clear that X*…even just 
from the very get-go it was like, you know…X had the right-just the right everything, the right demeanor, the right attitude, the right kind of can get it done, 
the right patient advocate.” 
 
“They’ve really formed these relationships with the patients and the patients are happy to go to the clinic and the patients are happy to see [the 
nurses]. The patients are happy to talk to them about their health care or about their sex lives, about their you name it. And there’s, like, some 
of the conversations that I’ve overheard as I’m walking up, ‘Ahh.’” 
Patient trust and mutual respect 
 
“So I think that the whole like concept of trust is so--it is at the core of what the health home is really about…I think the philosophy is absolutely 
transferrable [to other OTPs considering becoming health homes]. It’s not going to be the same people, right, but…you do have to show people that 
you…care about them, and that you trust them, and that they can trust you. That is absolutely transferrable [to other settings].” 
 
“I think [this story] really speaks to just the whole underlying feel of what our health home is about really…so [the nurse] went to an appointment with [a 
patient], they went to see a psychiatrist, a new psychiatrist, and…I guess X kind of walked in with this individual, and the psychiatrist was like, ‘Oh, well, 
why is [this person] here?  Why is X here?’ or, ‘Who is this?’  And so the patient was like, ‘Oh, well, this is X.  This is my nurse.’  And the psychiatrist was 
like, ‘Oh, okay, well, why is X here?’  And the patient was like, ‘Well, because I asked X to come.  X is my support.’  So X’s just kind of sitting there like, 
and then the psychiatrist goes, ‘Well, I don’t know if I feel comfortable having here, especially for like every visit.’ So the patient leans forward and goes 
well, ‘Well, when I trust you the same way that I trust X, then X won’t need to come with me anymore.’” 
Buy-in from clinical director(s) and counselors  
 
“Having the buy-in of the clinical directors...has been really helpful, because I'm not in charge of the counselors. I'm not their boss. I can't tell them what to 
do. They’re the ones who oversee the counseling staff. So they're the ones, like their buy-in is really important. Because they're the ones who are going to 
make sure various [health home] activities are getting done and documentation is happening and it's being done appropriately.” 
 
“I think the medical and counseling departments…work together, play nicely together.” 
Patient engagement 
 
“We do a ‘Fast Track’ health pass system. So if somebody is in the health home and they want to come in for a health home service, we actually allow them 




possible…it’s a perk to be in the health home because I get my fast track pass, I can get my medication five minutes sooner, you know. So then you feel 
special.” 
 
“Another way we try to really encourage patients to actually read [the health home newsletter] and interact is we do a quiz…so we collect all the quizzes, 
and we put them in a raffle, and then whoever gets picked gets a $25 gift card for a food store right over here.” 
 
“We budgeted for tokens for patients to get back and forth, not every day for every appointment, but sometimes if someone isn’t going to go to a doctor’s 
appointment because they can’t get there, we give them tokens and say ‘here, use these for the appointment.’” We budgeted things in like that.” 
Accessible and inviting physical space 
 
“One of the bigger things that we did here that we found has been really helpful is that we utilized space…where the traffic is heaviest to kind of, you know, 
capture as many people as we can for their monthly services, and things like that. So there were adjustments that we made in order to prioritize the health 
home being on that first floor, which is, you know, valuable real estate in this agency.” 
 
“Because I think to be successful, especially in the OTP setting, it’s about having--being accessible and I think we are -- that’s what we are here. We 
generally are 90+ percent on getting our contacts done for the month, and I think that’s because we’re here. We’ve very visible.” 
 
“So I think the fact that it’s voluntary and that it really is kind of, yes, we’re here, but [the nurses] make it kind of inviting to come, and so then people want 
to come back, and then when the word spreads, and like people just kind of want to come, and I think probably because the space is nice and it doesn’t look 
like a rundown building.” 
Collaboration between the OTP health homes 
 
“We’ve definitely had, I think, a lot of success with maintaining our relationship with them and just in general what’s working for you, what isn’t working, 
what can we improve even just working on things like policies and procedures for the programs like the questionnaire, what do you have, what are your 
thoughts. And then, I would say they usually meet in person like once every couple of weeks, but a lot of phone and email communication as well.” 
 
“Sometimes there are long period of time when we won’t talk but for the most part, we talk and we share information and we kind of support each other, 




“We have benefitted from kind of the knowledge and the experience that the other, that kind of the [PRP] pilot program did, had or offered. It hasn’t 
necessarily translated. Everything hasn’t really translated to us in an OTP. So I don’t want to say like it hasn’t been helpful at all, but you know, it just, you 





“We were really kind of like the pioneers of this, I mean, OTPs in particular. So there were issues that we ran into that probably weren’t anticipated.” 
 
 “I think that’s probably the one thing that is the mystery, is the CARF thing…it’s just like a mystery…I think we’re all nervous…we feel like we’re really 




Among OTP using existing staff: “The downside of all of that is..that there are so many things that X and I are both trained and know how to do, whether 
it’s dispensing…or whatever….plus, being [another role at OTP], I could be pulled in at a moment’s notice into some kind of emergency or we need to have 
a huddle about something, so I think that’s the one thing. I don’t just sit in my office and just use tunnel vision and just do health home.” 
 
“I think the [staffing] ratio that was put out by the state was not realistic in terms of the number…If I had a team of case managers with a ratio of 15 to 1. 
I’m just throwing out what I think the ratio for PRPs are. Could be a little bit different. But if I had the team on the ground that was taking the people to the 
appointments and everything and then just concentrating on really acute situations and a population study, sure…but the reality is in an [OPT] is that it’s 
going to probably be more the nurse doing more of the services and I don’t have a way. I haven’t come up with a solution on how it wouldn’t be.” 
 
“But that's really kind of not manageable, you know. Like for me, like I think I had 125 patients at one point, and to serve 125 patients in a month is really 
hard. Especially like our patients who have a lot going on physically and socially. You know, and I felt like me personally, like I couldn't provide the kind of 
care or services that I wanted to with it just being me.” 
Integration within OTP 
 
“I have to say that in the beginning sometimes I felt like the counselors were kind of dumping on the nurse managers, “Oh, well now I don’t 
have to deal with the patient with this,” and as soon as the patient brought up anything related to their health, which when we didn’t have the 
health home the counselors were dealing this and talking with them, helping them get appointments, and so it became like, ‘Hey, you guys can 
do a health home service as well,’ and they can, as long as it’s documented and so we created in our, we have an electronic record so we 
created a health home note and so they can do that as well and just getting them to realize all of the health home interactions that they were 
doing and that they weren’t documenting.” 
 
“What has been a little more of a challenge is really and…X has worked to implement this kind of much more--is the whole idea of integrating the health 
home [with the rest of the OTP] as opposed to kinda having it as an add-on ‘cause it has been challenging, right, and really getting the whole team to see 
that.” 
 
“When we first started the health home, one of the ideas was to really have one single unified treatment plan and that was really hard and that there was not 
buy-in for ‘cause the clinical supervisors were like ‘oh it’s gonna be too hard. What does that mean?’…I think that there’s no more buy-in for that than there 





Balancing time for high-need patients and healthier patients 
 
“I know that some of the challenges that-- I mean, some of the patients are overall relatively healthier than some others and so maybe they’re not quite as 
engaged and they’re just not here as often as some others.” 
 
“We have some people who are really, really sick, like medically really sick, and just then over all kind of medically, psychiatrically, psychosocially, kind of 
substance use disordered…and they take a lot of time.” 
Health information technology  
 
“It [the health IT system] doesn’t meet all our needs and we’re hoping that we’ll be getting more like, something even better but frankly, we’ve looked at 
lots of different things and they either don’t have a dosing system and then we’d have to pay for a separate health record and then a separate dosing system, 
so it’s been difficult to really find something.” 
 
“I mean it [current health IT system] works okay, but it’s not going to work for primary care, and that’s kind of a big expensive and undertaking it just in 
and of itself.” 
Billing 
 
“There were issues that we ran into that probably weren’t anticipated. Like for example, Medicaid pays OTPs a bundle rate. So there're very specific 
services that come with that rate. And we needed to make sure that weren't going to be double-dipping by having the counselors who are included in that 
bundled rate bill for services-- do services that Medicaid-- how do I say this? So Medicaid-- within the bundled rate, that the counselors worked, that 
Medicaid didn't see that counselor's work as being not just counseling patients on kind of their substance use disorder, but also on like contacting their 
primary care doctors, or helping them make appointments. We wanted to make sure that all of that wasn't included under the bundled rate. And so we had to 
get some guidance from DHMH and they got back to us and eventually said, ‘As long as it's not-- the service that's performed is not specifically relate to the 
substance use treatment, it can be considered a Health Home service and the counselors can bill for it. Even if they do the service at the same time they're 
doing their counseling session.’” 
 
“So the counselors were already basically doing services. They were calling doctors, they were setting up appointments. They were coordinating care. They 
were helping patients with their transportation needs, and housing and education, everything. I mean, those are all Health Home services. So kind of the next 
challenge was how do we get the counselors to now document those as Health Home services. And we're kind of still in that phase right now.” 
Serving non-eligible patients 
 
“I will say, one of the other things that just kills me is that we can’t involve people who are not Medicaid.” 
 
“There’s folks that would like to be in the health home that don’t meet the requirements. We try and help them or give some resources to counselors to help 
them. I don’t restrict our groups if--they’re open to anybody. I’ll just say it’s a health home-sponsored group but you’re welcome to come. I haven’t felt like 
there’s too many--there’s room in the group so why should I restrict people from coming? So that’s been our rule of thumb. I don’t feel comfortable saying I 




Specific health home services 
 
 “What we see here is a lot family members are completely written off, so they’ve completely given up on them, or family members who are really involved 
but just don’t want to come to the program or don’t trust methadone…it’s very rare that we find family members that are that engaged.” (referring to 
provision of family support) 
 
“We’re really good at delivering individual services...bringing those population [-level services] is probably the thing that we’re really trying to bring it 
home with a little bit more.” (referring to population health management) 
Lessons learned 
 Developing patient trust and mutual respect is important, particularly for a vulnerable population with long-standing mistrust of medical professionals. 
 Health homes in OTPs can play a critical role in educating other medical professionals about opioid addiction and medication assisted treatment. 
 Integrating other OTP staff, particularly counselors, is critical to ensuring that the health home can provide two services monthly to its patients. Also, staff 
can leverage the relationships with counselors and their patients, which are often long-standing. 
 Locating the health home in an attractive, high-traffic part of the OTP can promote patient engagement. 
 Health homes customize templates within their existing health IT systems to create “health home notes” that health home and counseling staff all can 
access. Staff use these “notes” to document the health home services that they provide and then the health home director enters this information into 
eMedicaid at the end of the month for billing purposes.  
 More developed electronic health records that meet the needs of OTPs are limited and pose a challenge to efforts to integrate behavioral and somatic care. 
 Health homes perceive the services they provide as potentially improving patients’ substance use disorders, not just somatic health conditions. 















 Changes in the funding mechanisms for OTP services (cuts to grant-based 
funding and shift to reliance on Medicaid) 
 Recent health systems-level changes as Maryland’s Primary Adult Care (PAC) 
has been phased down and Medicaid expansion rolled out  
 Transition from Medicaid managed care organizations (MCOs) to a new 
administrative services organization (ASO) 
 Integration of mental health and substance use agencies at state and city 
(Baltimore) levels  
Financial risk 
 Uncertainty about whether the health home reimbursements would be timely 
enough for OTPs to cover payroll and services  
 Unclear that health home would have a sufficient return on investment to 
justify adoption and start-up costs  
 Local OTPs owned by out-of-state companies have less influence over how 
these entities’ leadership makes decisions surrounding service expansion and 
costs  
 Hospital-based OTPs already reimbursed at a higher rate due to Hospital 
Services Cost Review Commission (HSCRC) regulations 
Staffing 
requirements 
 Risk of hiring new nursing staff if health home reimbursements end up being 
insufficient to cover costs 
 For smaller OTPs, would have to staff at a higher rate than makes sense fiscally 
 For hospital-based OTPs, added barrier of requiring higher-level hospital 
approval for new hiring  
 Not enough existing staff to support in the provision of health home services 





 OTPs with small patient base (<125 patients) would also need to provide 2 
health home services/month/patient for as many patients as possible, raising 
concerns about financial viability of hiring additional staff 
 If OTP is in a more rural setting, there is more limited provider network for 
referrals 
 Some small OTPs expressed disinclination to partner with other OTPs as part 
of a consortium for delivering health home services due to desire to partner 
only with OTPs that have similar treatment philosophy 
 No free physical space for health home to operate within OTP facility (i.e., 
space for exam room and nurse’s office) 
Separate 
accreditation 
 Cost of separate accreditation for health home (i.e., $7,000 for CARF health 
home accreditation) 
 Time and energy required to prepare for separate accreditation process 
 Some OTPs had just gone through accreditation process and earned 3-year 
CARF accreditation, and felt disinclined to go through another accreditation 
process 
 No example or model to follow  
Confusion about  
the health home 
Billing 
 Differentiating existing services provided from new health home services and 
preventing duplicative billing 
 Billing for specific services in order to get PMPM reimbursements for health 
home services is unfamiliar to OTPs, which are paid a bundled rate by 
Medicaid for their standard services 
Integration of health home into existing OTP infrastructure 
 Confusion about what the integration of the OTP and health home actually 
means in practice  




sort of transformational change perceived by some as a big undertaking 
Application 
 Misunderstanding about the standards section of the application 




 Variability among OTPs in: therapeutic approach to care; quality of services 
provided; scope of services provided; and willingness to adopt new programs  
 For-profit OTPs may be less inclined to provide additional services beyond 




 Some reluctance to invest in major organizational change if the health home 









This dissertation examined: (1) public stigma toward persons with prescription opioid 
addiction and implications for policy; (2) the effects of narratives framing prescription opioid 
addiction during pregnancy on public attitudes and policy support; and (3) facilitators and 
challenges associated with the implementation of health homes among Maryland opioid treatment 
programs (OTPs). In a nationally representative sample of Americans, we found social stigma 
toward persons with prescription opioid addiction to be high. Internal attributions for prescription 
opioid addiction were associated with greater stigma, suggesting that highlighting external 
contributors to untreated prescription opioid addiction may reduce stigma. Stigma toward this 
population was associated with greater public support for punitive approaches to the problem, 
such as the arrest and incarceration of doctor-shoppers, and lower support for public health-
oriented policies. Reducing stigma may increase public support for expanding treatment access 
and harm reduction strategies.  
In the second study, we found that reframing the experience of prescription opioid 
addiction during pregnancy through the use of narratives can reduce individual blame, increase 
perceptions of treatment effectiveness, and reduce support for punitive policy. However, the 
effects of the narratives depended on the socioeconomic status of the woman depicted in the 
narrative and whether or not she accessed treatment. Depicting the barriers to treatment access 
faced by a pregnant woman may be one strategy for increasing support for expanded insurance 
coverage for prescription opioid addiction treatment.  
Efforts to integrate substance use treatment services into the broader health care 
infrastructure face significant challenges. The third study in this dissertation highlighted the 
importance of addressing patient mistrust of medical providers and educating other clinicians 
with minimal experience working with this population about opioid addiction and medication 




home implementation due to their experience in successfully engaging with this vulnerable 
population. 
Social stigma toward this population likely varies geographically. Future research should 
explore whether stigma across communities is associated with availability of medication assisted 
treatment; findings may provide insight into how best to target efforts to reduce stigma. In 
addition, stigma on the part of health care providers toward patients with opioid use disorders is 
problematic because it reduces patients’ willingness to disclose substance use and to engage with 
the medical system. Message framing experiments targeting clinicians specifically could help to 
identify the communication strategies that might be most effective in reducing stigma among 
heath care providers. Finally, the Maryland opioid treatment programs implementing health 
homes hypothesized that their health homes were positively impacting enrollees’ non-opioid 
substance use in addition to their physical health. Evaluations of the health homes’ impact on 
patients with opioid addiction should examine the degree to which this intervention has affected 











Appendix 1.1: Socio-demographic characteristics of survey respondents in comparison to 






Female (%) 50.9 52.4 51.9 
Age (%) 
   
Ages 18-24 7.7 9.5 12.7 
Ages 25-34 15.1 20.1 17.5 
Ages 35-44 13.9 16.4 16.8 
Ages 45-54 19.1 17.4 18.4 
Ages 55-64 22.1 18.9 16.3 
Age 65 + 22.1 17.8 18.3 
Race (%) 
   
White only 71.6 66.9 66.0 
Black only 9.7 11.8 11.6 
Other 18.7 21.3 22.5 
Hispanic ethnicity (%) 
   
Hispanic   11.1 14.5 15.0 
Non-Hispanic 88.9 85.5 85.0 
Education (%) 
   
Less than high school degree 10.5 12.2 12.6 
High school degree 30.0 29.8 29.6 
Some college 29.7 29.3 28.9 
Bachelor's degree or higher 29.8 28.7 28.9 
Household income (%) 
   
Under $10,000 4.9 6.1 5.2 
$10,000-24,999 12.2 12.5 13.3 
$25,000-49,999 24.2 22.5 22.7 
$50,000-74,999 18.2 18.7 18.4 
$75,000 or higher 40.6 40.2 40.5 
Employment status (%) 
   
Employed 57.2 59.1 59.9 
Unemployed 8.2 9.8 4.9 
Retired 20.1 15.6 17.2 
Other (e.g., disabled, homemaker, 
other) 
14.6 15.5 18.1 
Region (%) 
   
Northeast 18.2 17.6 18.2 
Midwest 23.6 21.5 21.4 
South 35.3 37.9 37.1 




Appendix 1.2: Sensitivity analysis testing associations between causal attributions for prescription opioid misuse and binary measures of 
stigma using logistic regression models 
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allowed to deny 






allowed to deny 




Some people lack the self-discipline 
to use prescription pain medication 
without becoming addicted 
1.382 1.932** 2.413** 1.862** 1.599* 
[0.992 - 1.924] [1.366 - 2.733] [1.719 - 3.387] [1.335 - 2.596] [1.118 - 2.288] 
Some people do not understand how 
easy it is to become addicted to 
prescription pain medication 
1.335 1.335 2.020** 1.610* 1.005 
[0.904 - 1.972] [0.889 - 2.003] [1.372 - 2.974] [1.095 - 2.366] [0.678 - 1.488] 
Some people have a family history 
that makes them more likely to abuse 
prescription pain medications 
1.158 0.977 2.115** 1.426* 1.273 
[0.852 - 1.573] [0.707 - 1.350] [1.555 - 2.877] [1.053 - 1.933] [0.926 - 1.750] 
There has been inadequate research 
on the safety and effectiveness of 
prescription pain medications 
1.066 1.004 1.887** 1.078 1.460* 
[0.786 - 1.447] [0.719 - 1.402] [1.390 - 2.563] [0.796 - 1.460] [1.068 - 1.995] 
Pharmaceutical companies do not 
adequately explain the risks of 
addiction on labels of prescription 
pain medications 
1.339* 1.192 1.719** 1.510** 1.274 
[0.989 - 1.811] [0.863 - 1.645] [1.272 - 2.323] [1.118 - 2.039] [0.931 - 1.743] 
Pharmaceutical companies promote 
prescription pain medications 
without adequate knowledge of their 
safety and effectiveness 
1.128 1.119 1.844** 1.347* 1.415* 




Health insurance companies are 
more likely to pay for prescription 
pain medication than other pain 
treatments like physical therapy or 
acupuncture 
1.113 1.393 1.757** 1.489* 1.219 
[0.813 - 1.525] [1.000 - 1.942] [1.285 - 2.401] [1.087 - 2.038] [0.880 - 1.690] 
a
 Odds ratios adjust for age, gender, educational attainment, race, household income, MSA residence, political ideology, and personal experience with 
prescription opioids. Estimates incorporate survey weights to account for complex sampling design. 






Appendix 1.3: Sensitivity analysis testing associations between causal attributions for prescription opioid misuse and addiction and binary 
measures of stigma using logistic regression models 
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allowed to deny 






allowed to deny 




Individuals addicted to prescription 
opioids 
1.775** 2.856** 2.480** 2.549** 2.475** 
[1.166 - 2.703] [1.863 - 4.380] [1.626 - 3.780] [1.648 - 3.943] [1.499 - 4.086] 
Individuals who illegally sell 
prescription opioids 
1.315 2.156** 1.860** 1.637* 1.624* 
[0.875 - 1.977] [1.419 - 3.275] [1.232 - 2.808] [1.075 - 2.493] [1.044 - 2.526] 
Pharmacies and pharmacists 
1.158 1.317 1.756** 1.324 0.95 
[0.838 - 1.599] [0.944 - 1.839] [1.277 - 2.414] [0.964 - 1.819] [0.683 - 1.322] 
Pharmaceutical companies 
1.052 1.341 1.392* 1.192 1.105 
[0.763 - 1.450] [0.963 - 1.868] [1.017 - 1.905] [0.871 - 1.632] [0.795 - 1.534] 
Government 
0.956 1.157 1.583** 0.981 1.162 
[0.707 - 1.294] [0.840 - 1.595] [1.167 - 2.147] [0.725 - 1.327] [0.852 - 1.586] 
Doctors 
1.443 2.350** 1.892** 1.403 1.206 
[0.984 - 2.117] [1.593 - 3.466] [1.305 - 2.743] [0.961 - 2.046] [0.815 - 1.785] 
Health insurance companies 
1.049 1.119 1.757** 1.212 1.251 
[0.775 - 1.419] [0.812 - 1.542] [1.298 - 2.378] [0.899 - 1.635] [0.918 - 1.705] 
Law enforcement 
1.188 1.316 1.823** 1.607** 1.504* 
[0.880 - 1.604] [0.960 - 1.805] [1.343 - 2.473] [1.191 - 2.169] [1.102 - 2.053] 
a
 Odds ratios adjust for age, gender, educational attainment, race, household income, MSA residence, political ideology, and personal experience with 








Appendix 1.4: Sensitivity analysis estimating association between stigma and policy support in logistic regression models  
 



























Passing laws to 
protect people 
from criminal 
charges for drug 
crimes if they seek 


























Stigma scale  1.564** 0.888 0.913 0.981 0.981 
 
[1.350 - 1.812] [0.784 - 1.006] [0.812 - 1.025] [0.867 - 1.110] [0.866 - 1.112] 
Age (years) 1.014** 1.006 1.005 0.997 1.011* 
  [1.004 - 1.024] [0.996 - 1.015] [0.996 - 1.014] [0.988 - 1.006] [1.001 - 1.021] 
Female gender 0.978 1.248 0.92 1.019 1.178 
 
[0.704 - 1.357] [0.918 - 1.697] [0.685 - 1.235] [0.753 - 1.379] [0.869 - 1.598] 
Educational attainment (reference: High school education) 
Less than HS 0.826 0.599 0.817 1.043 0.714 
  [0.471 - 1.451] [0.339 - 1.057] [0.478 - 1.397] [0.619 - 1.759] [0.405 - 1.261] 
Some college 0.99 1.184 1.102 0.655* 1.085 
  [0.634 - 1.546] [0.802 - 1.747] [0.754 - 1.609] [0.441 - 0.973] [0.729 - 1.614] 
Bachelor’s degree + 0.668 1.531 1.245 0.703 0.988 
 
[0.424 - 1.052] [0.998 - 2.347] [0.834 - 1.858] [0.463 - 1.068] [0.647 - 1.508] 
Race (reference: white) 
     




  [0.379 - 1.072] [0.495 - 1.368] [0.456 - 1.237] [0.435 - 1.226] [0.643 - 1.815] 
Other race 1.374 1.26 1.303 1.184 1.412 
 
[0.864 - 2.185] [0.807 - 1.966] [0.857 - 1.982] [0.776 - 1.806] [0.911 - 2.188] 
Income category (reference: $75,000 or higher) 
Under $10,000 0.288** 0.984 0.575 1.112 0.659 
 
[0.124 - 0.667] [0.462 - 2.095] [0.276 - 1.196] [0.529 - 2.337] [0.297 - 1.464] 
$10,000-24,999 0.696 0.91 0.824 1.630 1.01 
 
[0.404 - 1.199] [0.554 - 1.495] [0.501 - 1.355] [0.964 - 2.755] [0.604 - 1.688] 
$25,000-49,999 0.749 1.050 0.841 1.200 1.264 
  [0.487 - 1.151] [0.685 - 1.609] [0.562 - 1.256] [0.793 - 1.816] [0.827 - 1.930] 
$50,000-74,999 1.394 0.998 0.872 1.222 1.15 
  [0.860 - 2.260] [0.646 - 1.544] [0.576 - 1.320] [0.800 - 1.867] [0.762 - 1.734] 
Lives in MSA  0.624* 1.083 0.903 1.570* 1.595* 
 
[0.397 - 0.981] [0.720 - 1.630] [0.604 - 1.351] [1.025 - 2.404] [1.049 - 2.425] 
Political ideology  (reference: liberal) 
Moderate 0.839 0.540** 0.662* 0.692* 0.450** 
 
[0.530 - 1.329] [0.348 - 0.836] [0.440 - 0.996] [0.460 - 1.042] [0.299 - 0.677] 
Conservative 0.761 0.234** 0.566* 0.491** 0.185** 
 
[0.447 - 1.296] [0.141 - 0.388] [0.353 - 0.909] [0.304 - 0.792] [0.112 - 0.306] 
Personal experience with 
prescription opioid abuse 
1.376 1.464* 1.008 1.733** 1.086 
[0.958 - 1.976] [1.043 - 2.054] [0.730 - 1.392] [1.254 - 2.395] [0.777 - 1.519] 
Constant 0.280* 2.039 2.119 0.734 0.703 
 
[0.101 - 0.770] [0.754 - 5.515] [0.837 - 5.367] [0.289 - 1.863] [0.267 - 1.853] 
Observations 1,073 1,069 1,071 1,070 1,072 
a
 Odds ratios adjust for age, gender, educational attainment, race, household income, MSA residence, political ideology, and personal experience with 
prescription opioids. Estimates incorporate survey weights to account for complex sampling design. 







Appendix 1.5a: Measures of R-squared values from OLS regression models testing contributions of stigma scale, political ideology, and 




Arresting and prosecuting people who obtain 
multiple prescriptions for pain medication at the 
same time from different doctors 
Expanding Medicaid insurance benefits to require 
coverage for treatment of substance abuse problems, 





Model 2:  
Adds ideology 
Model 3:  
Adds stigma 
Model 1:  
Socio-
demographic  
Model 2:  
Adds ideology 
Model 3:  
Adds stigma 
Stigma scale     0.391**     -0.127* 
      [0.291, 0.491]     [-0.230, -0.023] 
Political ideology (Re: Liberal)   
 
    
 
  
Moderate   0.027 -0.111   -0.517** -0.472** 
    [-0.283, 0.337] [-0.430, 0.208]   [-0.801, -0.233] [-0.757, -0.188] 
Conservative   0.194 -0.065   -1.382** -1.298** 
    [-0.170, 0.559] [-0.434, 0.303]   [-1.741, -1.024] [-1.659, -0.937] 
Age (years) 0.009** 0.008* 0.005 0.001 0.004 0.005 
  [0.003, 0.016] [0.002, 0.015] [-0.001, 0.012] [-0.007, 0.008] [-0.003, 0.011] [-0.002, 0.012] 
Female gender 0.061 0.046 0.083 0.446** 0.364** 0.351** 
  [-0.155, 0.277] [-0.174, 0.267] [-0.129, 0.295] [0.214, 0.679] [0.139, 0.588] [0.126, 0.575] 
Educational attainment (Ref: high school education)      
 
  
Less than high school -0.011 -0.014 -0.019 -0.260 -0.321 -0.318 
  [-0.389, 0.367] [-0.404, 0.377] [-0.404, 0.366] [-0.694, 0.174] [-0.755, 0.113] [-0.748, 0.112] 




  [-0.454, 0.124] [-0.464, 0.121] [-0.378, 0.190] [-0.290, 0.321] [-0.385, 0.205] [-0.409, 0.179] 
Bachelor's or higher -0.349* -0.331* -0.273 0.383* 0.257 0.238 
  [-0.651, -0.048] [-0.630, -0.031] [-0.563, 0.017] [0.051, 0.714] [-0.068, 0.583] [-0.088, 0.564] 
Race (Ref: white)   
 
    
 
  
Black/African American -0.076 -0.015 0.000 0.125 0.003 -0.001 
  [-0.442, 0.290] [-0.405, 0.375] [-0.361, 0.361] [-0.267, 0.517] [-0.379, 0.385] [-0.382, 0.381] 
Other race 0.311* 0.318* 0.321* 0.203 0.169 0.166 
  [0.011, 0.610] [0.018, 0.618] [0.021, 0.622] [-0.122, 0.528] [-0.154, 0.491] [-0.150, 0.482] 
Household income category (Ref: >$75,000)      
 
  
<$10,000 -0.695* -0.762* -0.566 0.573* 0.343 0.280 
  [-1.255, -0.134] [-1.356, -0.168] [-1.170, 0.039] [0.038, 1.109] [-0.172, 0.859] [-0.246, 0.805] 
$10,000-24,999 -0.316 -0.327 -0.219 0.384* 0.247 0.212 
  [-0.706, 0.074] [-0.718, 0.064] [-0.607, 0.168] [0.003, 0.765] [-0.125, 0.620] [-0.156, 0.579] 
$25,000-49,999 -0.231 -0.218 -0.167 0.184 0.195 0.177 
  [-0.528, 0.066] [-0.518, 0.082] [-0.446, 0.113] [-0.140, 0.508] [-0.122, 0.511] [-0.141, 0.496] 
$50,000-74,999 0.064 0.056 0.133 0.011 0.005 -0.023 
  [-0.229, 0.357] [-0.240, 0.352] [-0.155, 0.421] [-0.332, 0.355] [-0.321, 0.332] [-0.343, 0.297] 
MSA residence -0.286* -0.274 -0.175 0.276 0.184 0.153 
  [-0.567, -0.006] [-0.556, 0.008] [-0.439, 0.090] [-0.035, 0.588] [-0.105, 0.473] [-0.135, 0.441] 
Personal experience with 
prescription opioids 
0.149 0.158 0.147 0.145 0.141 0.144 
[-0.092, 0.390] [-0.087, 0.403] [-0.090, 0.384] [-0.115, 0.404] [-0.107, 0.389] [-0.101, 0.390] 
Constant 5.223** 5.170** 3.418** 3.911** 4.621** 5.191** 
  [4.732, 5.714] [4.599, 5.742] [2.708, 4.128] [3.359, 4.462] [4.029, 5.213] [4.439, 5.944] 
    
 
    
 
  
Observations 1099 1073 1073 1095 1069 1069 




*** p<0.01, ** p<0.05, *p<0.1     
This table displays coefficients from linear regression models estimating changes in policy support (on a 1-7 scale), adjusting for covariates. Estimates 






Appendix 1.5b: Measures of R-squared values from OLS regression models testing contributions of stigma, political ideology, and socio-
demographic characteristics in explaining variation in policy support (Part II of III) 
 
  
Passing laws to protect people from criminal charges 
for drug crimes if they seek medical help for 
themselves or others experiencing a prescription 
opioid overdose 
Providing naloxone to friends and family members 





Model 2:  
Adds ideology 
Model 3:  
Adds stigma 
Model 1:  
Socio-
demographic  
Model 2:  
Adds ideology 
Model 3:  
Adds stigma 
Stigma scale     -0.131*     -0.065 
      [-0.228, -0.033]     [-0.168, 0.039] 
Political ideology (Ref: Liberal)           
Moderate   -0.247 -0.202   -0.246 -0.226 
    [-0.548, 0.054] [-0.497, 0.093]   [-0.544, 0.053] [-0.525, 0.074] 
Conservative   -0.535* -0.448*   -0.721** -0.681** 
    [-0.911, -0.159] [-0.817, -0.079]   [-1.079, -0.364] [-1.041, -0.321] 
Age (years) 0.002 0.003 0.004 0.001 0.003 0.003 
  [-0.005, 0.008] [-0.004, 0.009] [-0.003, 0.010] [-0.006, 0.008] [-0.004, 0.010] [-0.003, 0.010] 
Female gender 0.084 0.083 0.070 0.060 0.018 0.011 
  [-0.143, 0.312] [-0.147, 0.312] [-0.159, 0.299] [-0.159, 0.280] [-0.202, 0.239] [-0.210, 0.232] 
Educational attainment (Ref: high school education)        
Less than high school -0.011 -0.084 -0.081 0.071 0.027 0.028 
  [-0.414, 0.393] [-0.501, 0.334] [-0.498, 0.337] [-0.349, 0.491] [-0.394, 0.447] [-0.390, 0.446] 
Some college 0.054 0.037 0.012 -0.231 -0.262 -0.275 




Bachelor's or higher 0.424** 0.386* 0.366* -0.223 -0.247 -0.255 
  [0.105, 0.743] [0.0659, 0.707] [0.045, 0.686] [-0.522, 0.076] [-0.547, 0.054] [-0.557, 0.047] 
Race (Reference: white)             
Black/African American 0.163 0.097 0.092 0.016 -0.010 -0.013 
  [-0.196, 0.523] [-0.272, 0.465] [-0.280, 0.463] [-0.340, 0.371] [-0.373, 0.352] [-0.378, 0.352] 
Other race 0.207 0.236 0.233 0.170 0.180 0.179 
  [-0.122, 0.536] [-0.087, 0.560] [-0.087, 0.553] [-0.143, 0.484] [-0.129, 0.489] [-0.128, 0.486] 
HH income category (Ref: >$75,000)        
<$10,000 -0.109 0.018 -0.048 0.425 0.369 0.336 
  [-0.702, 0.484] [-0.558, 0.595] [-0.630, 0.533] [-0.099, 0.948] [-0.173, 0.912] [-0.203, 0.874] 
$10,000-24,999 0.092 0.023 -0.015 0.425* 0.372 0.353 
  [-0.304, 0.488] [-0.377, 0.422] [-0.414, 0.383] [0.047, 0.803] [-0.013, 0.757] [-0.033, 0.739] 
$25,000-49,999 0.119 0.115 0.097 0.263 0.261 0.251 
  [-0.189, 0.427] [-0.199, 0.429] [-0.219, 0.413] [-0.035, 0.561] [-0.039, 0.561] [-0.050, 0.552] 
$50,000-74,999 0.072 0.050 0.021 0.163 0.137 0.123 
  [-0.233, 0.378] [-0.253, 0.353] [-0.277, 0.319] [-0.149, 0.475] [-0.167, 0.441] [-0.178, 0.425] 
MSA residence 0.217 0.186 0.153 0.197 0.177 0.161 
  [-0.140, 0.574] [-0.168, 0.540] [-0.202, 0.509] [-0.123, 0.518] [-0.131, 0.484] [-0.147, 0.468] 
Personal experience with 
prescription opioids 
-0.075 -0.092 -0.088 0.340** 0.356** 0.358** 
[-0.326, 0.177] [-0.343, 0.159] [-0.336, 0.159] [0.095, 0.585] [0.114, 0.599] [0.117, 0.598] 
Constant 4.026** 4.325** 4.913** 3.922** 4.229** 4.520** 
  [3.432 - 4.621] [3.662 - 4.988] [4.085 - 5.741] [3.385 - 4.458] [3.649 - 4.809] [3.742 - 5.297] 
              
Observations 1097 1071 1071 1096 1070 1070 
R-squared 0.020 0.033 0.043 0.038 0.063 0.065 




This table displays coefficients from linear regression models estimating changes in policy support (on a 1-7 scale), adjusting for covariates. Estimates 




Appendix 1.5c: Measures of R-squared values from OLS regression models testing 
contributions of scale, political ideology, and socio-demographic characteristics in 
explaining variation in policy support (Part III of III) 
 
  
Increasing government spending to improve 
treatment of substance abuse problems, including 
addiction to prescription opioids 
  
Model 1:  
Socio-
demographic  
Model 2:  
Adds ideology 
Model 3:  
Adds stigma 
Stigma scale     -0.144** 
      [-0.250, -0.0375] 
Political ideology (Ref: Liberal)       
Moderate   -0.556** -0.506** 
    [-0.832, -0.279] [-0.780, -0.231] 
Conservative   -1.580** -1.484** 
    [-1.950, -1.210] [-1.849, -1.120] 
Age (years) 0.002 0.005 0.006 
  [-0.005, 0.009] [-0.002, 0.012] [-0.001, 0.013] 
Female gender 0.299* 0.208 0.195 
  [0.059, 0.539] [-0.026, 0.442] [-0.038, 0.428] 
Educational attainment (Ref: high school education)      
Less than high school -0.176 -0.255 -0.251 
  [-0.607, 0.256] [-0.671, 0.160] [-0.659, 0.157] 
Some college 0.014 -0.068 -0.096 
  [-0.298, 0.326] [-0.372, 0.236] [-0.399, 0.206] 
Bachelor's or higher -0.004 -0.135 -0.160 
  [-0.350, 0.343] [-0.467, 0.197] [-0.495, 0.176] 
Race (Reference: White)       
Black/African American 0.465* 0.299 0.293 
  [0.103, 0.827] [-0.071, 0.668] [-0.078, 0.665] 
Other race 0.272 0.283 0.279 
  [-0.073, 0.618] [-0.051, 0.618] [-0.048, 0.607] 
Household income category (Ref: 
>$75,000) 
      
<$10,000 0.229 0.087 0.014 
  [-0.303, 0.760] [-0.453, 0.627] [-0.539, 0.567] 
$10,000-24,999 0.262 0.097 0.057 




$25,000-49,999 0.183 0.202 0.182 
  [-0.147, 0.512] [-0.117, 0.521] [-0.139, 0.503] 
$50,000-74,999 0.011 -0.018 -0.048 
  [-0.331, 0.352] [-0.333, 0.297] [-0.356, 0.259] 
MSA residence 0.430* 0.314 0.278 
  [0.0549, 0.804] [-0.024, 0.652] [-0.057, 0.613] 
Personal experience with 
prescription opioids 
0.002 -0.009 -0.004 
  [-0.272, 0.275] [-0.263, 0.246] [-0.253, 0.246] 
Constant 3.631** 4.438** 5.084** 
  [3.040 - 4.222] [3.810 - 5.065] [4.282 - 5.887] 
        
Observations 1098 1072 1072 
R-squared 0.032 0.125 0.135 
*** p<0.01, ** p<0.05, *p<0.1 
This table displays coefficients from linear regression models estimating changes in policy support (on a 1-










Appendix 2.1: Narrative text  
 
Group 1: Control group, N=264 
 
No narrative text 
 
Group 2: Low SES base narrative, N=285 
 
Michelle is a woman in her early twenties who began working at a fast food restaurant after 
she dropped out of high school. She lives in a government-subsidized apartment. Two months 
ago, Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries 
and she had to have surgery. After the surgery, she still had severe pain in her back and hips so 
her doctor prescribed OxyContin, a narcotic pain medication. Three months after her back 
surgery, she was still feeling a lot of pain so her doctor prescribed her a higher dose of 
OxyContin. Michelle began taking more pills to try to control the pain and sometimes ran out 
before her next refill. When she ran out, she felt anxious, became sweaty and nauseous, and 
had trouble sleeping.  These symptoms lasted until she was able to get more pills. Her doctor 
refused to give her more pills before her next scheduled refill, so Michelle sometimes took the 
bus to other parts of town to get more pills from other doctors. Her family and friends noticed 
that Michelle‘s behavior had changed, and that she was borrowing money that she didn’t 
repay.  When Michelle’s family found out that she was pregnant, they told her that they were 
worried about the pills she was taking and urged her to get help. 
 
Word count = 232 
 
Group 2: High SES base narrative, N=269 
 
Michelle is a woman in her early thirties who began working as the regional manager of a 
restaurant chain after getting her Master’s degree in Business Administration. She lives in a 
new house with her husband. Two months ago, Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries 
and she had to have surgery. After the surgery, she still had severe pain in her back and hips so 
her doctor prescribed OxyContin, a narcotic pain medication. Three months after her back 
surgery, she was still feeling a lot of pain so her doctor prescribed her a higher dose of 
OxyContin. Michelle began taking more pills to try to control the pain and sometimes ran out 
before her next refill. When she ran out, she felt anxious, became sweaty and nauseous, and 
had trouble sleeping.  These symptoms lasted until she was able to get more pills. Her doctor 
refused to give her more pills before her next scheduled refill, so Michelle sometimes drove to 
other parts of town to get more pills from other doctors. Her family and friends noticed that 
Michelle‘s behavior had changed, and her husband noticed money missing from their bank 
account.  When Michelle’s family found out that she was pregnant, they told her that they 
were worried about the pills she was taking and urged her to get help. 
 
Word count = 237 
 





Michelle is a woman in her early twenties who began working at a fast food restaurant after 
she dropped out of high school. She lives in a government-subsidized apartment. Two months 
ago, Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries 
and she had to have surgery. After the surgery, she still had severe pain in her back and hips so 
her doctor prescribed OxyContin, a narcotic pain medication. Three months after her back 
surgery, she was still feeling a lot of pain so her doctor prescribed her a higher dose of 
OxyContin. Michelle began taking more pills to try to control the pain and sometimes ran out 
before her next refill. When she ran out, she felt anxious, became sweaty and nauseous, and 
had trouble sleeping.  These symptoms lasted until she was able to get more pills. Her doctor 
refused to give her more pills before her next scheduled refill, so Michelle sometimes took the 
bus to other parts of town to get more pills from other doctors. Her family and friends noticed 
that Michelle‘s behavior had changed, and that she was borrowing money that she didn’t 
repay.  When Michelle’s family found out that she was pregnant, they told her that they were 
worried about the pills she was taking and urged her to get help. 
 
Michelle took the concerns of her family to heart. She was worried that her inability to stop 
taking OxyContin might cause problems during her pregnancy. Michelle’s doctor 
recommended that she begin taking methadone, a medical treatment for addiction, on a daily 
basis. He explained to Michelle that abruptly stopping the OxyContin would cause withdrawal 
symptoms that might put her health and the baby’s wellbeing at risk.  
 
However, when Michelle called a nearby methadone treatment center, they told her that there 
was a long waiting list. Michelle desperately wanted to begin treatment as soon as possible. 
She found another treatment center two hours away that had a spot for her. However, Michelle 
had trouble getting to the treatment center because she didn’t have a car. She felt embarrassed 
asking friends for help because she didn’t want them to know about the problems she was 
dealing with while pregnant. She was grateful to family members who helped out 
occasionally, but no one could take her every day. Taking a taxi was too much money and 
there was no bus line between the two towns. The nurse at the methadone center told her that 
she needed to be there every day for the treatment to be effective. Traveling four hours round-
trip on the days she was able to find a ride became exhausting and began to create problems 
for Michelle at work. Her manager became angry when she was repeatedly late for shifts and 
threatened to let her go. Michelle missed days of treatments and began using OxyContin 
again. She felt guilty and ashamed. 
 
Word count = 493 
 





Michelle is a woman in her early twenties who began working at a fast food restaurant after 
she dropped out of high school. She lives in a government-subsidized apartment. Two months 
ago, Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries 
and she had to have surgery. After the surgery, she still had severe pain in her back and hips so 
her doctor prescribed OxyContin, a narcotic pain medication. Three months after her back 
surgery, she was still feeling a lot of pain so her doctor prescribed her a higher dose of 
OxyContin. Michelle began taking more pills to try to control the pain and sometimes ran out 
before her next refill. When she ran out, she felt anxious, became sweaty and nauseous, and 
had trouble sleeping.  These symptoms lasted until she was able to get more pills. Her doctor 
refused to give her more pills before her next scheduled refill, so Michelle sometimes took the 
bus to other parts of town to get more pills from other doctors. Her family and friends noticed 
that Michelle‘s behavior had changed, and that she was borrowing money that she didn’t 
repay.  When Michelle’s family found out that she was pregnant, they told her that they were 
worried about the pills she was taking and urged her to get help. 
 
Michelle took the concerns of her family to heart. She was worried that her inability to stop 
taking OxyContin might cause problems during her pregnancy. Michelle’s doctor 
recommended that she begin taking methadone, a medical treatment for addiction, on a daily 
basis. He explained to Michelle that abruptly stopping OxyContin would cause withdrawal 
symptoms that might put her health and the baby’s wellbeing at risk. Michelle was able to 
enroll in a methadone program near her home. With the help of this program and working with 
a counselor, Michelle had a healthy pregnancy. Her treatment has continued successfully and 
she hasn’t used OxyContin or other narcotic prescription pain medications in over two years. 
 
Word count = 345 
Group 6: High SES narrative with successful treatment, N=274 
 
Michelle is a woman in her early thirties who began working as the regional manager of a 
restaurant chain after getting her Master’s degree in Business Administration. She lives in a 
new house with her husband. Two months ago, Michelle learned that she was pregnant.  
 
Last year, Michelle was hit by a car. The accident left her with back, hip, and knee injuries 
and she had to have surgery. After the surgery, she still had severe pain in her back and hips so 
her doctor prescribed OxyContin, a narcotic pain medication. Three months after her back 
surgery, she was still feeling a lot of pain so her doctor prescribed her a higher dose of 
OxyContin. Michelle began taking more pills to try to control the pain and sometimes ran out 
before her next refill. When she ran out, she felt anxious, became sweaty and nauseous, and 
had trouble sleeping.  These symptoms lasted until she was able to get more pills. Her doctor 
refused to give her more pills before her next scheduled refill, so Michelle sometimes drove to 
other parts of town to get more pills from other doctors. Her family and friends noticed that 
Michelle‘s behavior had changed, and her husband noticed money missing from their bank 
account.  When Michelle’s family found out that she was pregnant, they told her that they 
were worried about the pills she was taking and urged her to get help. 
 
Michelle took the concerns of her family to heart. She was worried that her inability to stop 
taking OxyContin might cause problems during her pregnancy. Michelle’s doctor 




basis. He explained to Michelle that abruptly stopping OxyContin would cause withdrawal 
symptoms that might put her health and the baby’s wellbeing at risk. Michelle was able to 
enroll in a methadone program near her home. With the help of this program and working with 
a counselor, Michelle had a healthy pregnancy. Her treatment has continued successfully and 
she hasn’t used OxyContin or other narcotic prescription pain medications in over two years. 
 












Prescription pain medications are narcotic medications prescribed by a doctor to treat pain. 
These do not include "over-the-counter" pain relievers such as aspirin, Tylenol, or Advil that 
can be bought in drug stores or grocery stores without a doctor's prescription.  To see 
examples of prescription pain medications, please click here. 
 
VICODIN®, LORTAB®, NORCO®, OR LORCET®/LORCET PLUS®, PERCOCET®, 
PERCODAN®, OR TYLOX®, OXYCONTIN®, HYDROCODONE, MORPHINE, 
KADIAN®, OXYCODONE, TRAMADOL, ULTRAM®, CODEINE, TYLENOL® WITH 
CODEINE, METHADONE, DILAUDID®, FIORICET®, FIORINAL®, OPANA®, 
OXYMORPHONE, BUPRENORPHINE, SUBOXONE, SUBUTEX, DARVOCET-N®, 
DARVON®, OR PROPOXYPHENE, DEMEROL® 
 






Appendix 2.3: Weighted and Un-Weighted Characteristics of Survey Respondents 





Female (%) 51.1 51.6 51.9 
Age (%) 
   
Ages 18-24 9.7 12.2 12.7 
Ages 25-34 15.9 18.4 17.5 
Ages 35-44 15.5 15.9 16.8 
Ages 45-54 18.2 16.5 18.4 
Ages 55-64 21.8 19.7 16.3 
Age 65 + 19.0 17.4 18.3 
Race (%) 
   
White only 73.4 65.4 66.0 
Black only 9.6 11.4 11.6 
Other 17.0 23.1 22.5 
Hispanic ethnicity 
   
Hispanic   9.8 15.2 15.0 
Non-Hispanic 90.2 84.8 85.0 
Education (%) 
   
< High school degree 10.7 12.3 12.6 
High school degree 31.5 29.7 29.6 
Some college 26.9 28.7 28.9 
Bachelor's degree or higher 30.9 29.3 28.9 
Household income (%) 
   
Under $10,000 5.0 5.2 5.2 
$10,000-24,999 14.1 12.6 13.3 
$25,000-49,999 22.1 22.4 22.7 
$50,000-74,999 19.0 18.8 18.4 
$75,000 or higher 39.9 41.1 40.5 
Employment status (%) 
   
Employed 57.7 59.1 59.9 
Unemployed 7.5 8.5 4.9 
Retired 19.8 18.0 17.2 
Other (e.g., disabled, 
homemaker, other) 
15.1 14.4 18.1 
Region (%) 
   
Northeast 19.3 18.4 18.2 
Midwest 23.6 21.4 21.4 
South 35.4 36.6 37.1 
West 21.7 23.5 23.4 
Political Party Affiliation (%)    
Republican 26.8 24.9 23.5 
Independent 41.0 41.2 43.3 




Note: GfK KnowledgeNetworks sample weights used to calculate descriptive statistics. For socio-
demographic characteristics, comparison data extracted from the March 2013 Current Population Survey. 









Test of randomization across 6 
groups 
Female   51.6 Pearson X
2
 = 0.316; p=0.998 




 = 14.854; p=0.978 
Ages 18-24 12.2 
 
Ages 25-34 18.4 
 
Ages 35-44 15.9 
 
Ages 45-54 16.5 
 
Ages 55-64 19.7 
 
Age 65 + 17.4 
 




 = 0.372; p=1.000 
White only 65.4 
 








 = 0.221; p=0.999 








 = 0.671; p=1.000 
< High school degree 12.3 
 
High school degree 29.7 
 
Some college 28.7 
 
Bachelor's degree or higher 29.3 
 




 = 6.876; p=0.999 








$75,000 or higher 41.1 
 




























Political Party Affiliation  Pearson X
2
 = 16.156; p=0.160 
Republican 24.9  
Independent 41.2  




   Note: Chi square tests were used to test differences across study groups. GfK KnowledgeNetworks 







Appendix 3.1: Health home staffing requirements 
 
Position Time requirements Qualifications Responsibilities 
Health home 
director 
0.5 FTE  / 0-249 enrollees 
1.0 FTE / 250-374 enrollees 
1.5 FTE / 375-499 enrollees 
2 FTE / 500-624 enrollees 
2.5 FTE / 625-749 enrollees 
3.0 FTE / 750-874 enrollees 
3.5 FTE / 875-999 enrollees 
i. Bachelor’s degree + 2 
years health administration 
experience, or 
ii. Master’s degree, or 
iii. licensed RN, or 
iv. licensed physician or NP 
 Leads implementation and coordination 
 Leads practice transformation 
 Develops and maintains relationships with external providers 
 Monitors health home performance at population and participant 
level and leads quality improvement efforts 
 Designs and develops prevention and wellness initiatives 
Health home 
care manager 
0.5 FTE  / 0-249 enrollees 
1.0 FTE / 250-374 enrollees 
1.5 FTE / 375-499 enrollees 
2 FTE / 500-624 enrollees 
2.5 FTE / 625-749 enrollees 
3.0 FTE / 750-874 enrollees 
3.5 FTE / 875-999 enrollees 
i. RN or NP, or 
ii. PA under supervision of 
physician 
 Develops wellness and prevention initiatives 
 Facilitates health education groups 
 Participates in care plan development for enrollees 
 Consults with staff about health conditions 
 Assists in contacting medical providers 
 Providers training on medical issues 
 Tracks assessments and screenings for patients 
 Assists in implementing IT programs and initiatives 
 Monitors health IT systems, including CRISP 




1.5 hours / enrollee / year MD or NP  Reviews and signs off on initial intake assessments 
 Participates in treatment planning, case reviews 
 Consults with other practitioners in the health home 
 Consults regarding particular enrollee issues 
 Assists in coordinating with external providers 
 Provides staff training 





Appendix 3.2: Interview guides 
 
Opioid Treatment Program Health Home Interview Guide 
 
1. What were the primary factors contributing to the OTP’s decision to apply to become a health 
home?  
 
2. Describe the adoption and implementation timeline to-date and any important objectives in 
the near future. Begin with adoption and transition period and then we can move onto the 
current state of implementation and finish with discussion of future directions and goals for 
this health home. 
 
3. What were your main concerns, if any, about becoming a health home? 
 
4. How has your work flow as [position on health home] changed as a result of the health home 
implementation?  
 
5. What have been the most significant barriers the OTP has faced during the process of 
implementing the health home so far? 
 
6. What have been the most important facilitators of the process of implementing the health 
home so far? 
 
7. How have patients responded to the health home?  
a. Has the OTP health home solicited patient feedback during the implementation process?  
b. How has the OTP / health home staff responded to patient criticism (if any) of the 
implementation process? 
c. How have the needs of your patients influenced the implementation of the health home? 
How have you adapted the health home model to address patient needs? 
 
8. How do you obtain and track patient information for internal quality improvement efforts? 
Do you use the eMedicaid system for these purposes or your regular health IT system? 
 
9. Do you think the health home implementation has affected the experience of patients in the 
OTP who are not eligible to participate in the health home (e.g., not insured through 
Medicaid, no chronic illness)? In what ways? 
 
10. What are the particular strengths of this OTP that have made it a good candidate for 
becoming a health home? 
 
11. In what ways do you think your organization differs from OTPs that have not applied to 
become health homes?  
 
12. Why do you think other OTPs have not applied to become a health home? 
 
13. What advice would you have for other OTPs interested in applying to become a Medicaid 
health home? 
 
14. What additional assistance could the Maryland Medicaid office provide to OTP health homes 





15. What support or guidance have you obtained from local substance use treatment 
organizations? (e.g., Behavioral Health System Baltimore, National Council on Alcoholism 
and Drug Dependence of Maryland, Maryland Addictions Directors Council, Maryland 
Association of Addiction Professionals, Baltimore City Needle Exchange, or others) 
 
16. Is there anything I missed that you want to share about the OTP health home demonstration 
or your health home’s experience? 
 
17. Is there anyone that you would recommend I talk to at [this OTP health home / partner 
organization / other OTP]?  
 
18. Is there anyone that you would recommend I talk to at a partner organization, local non-
profit, or consumer advocacy organization? 
 
 
Opioid Treatment Program (non-adopter) Interview Guide 
 
1. Can you tell me about your OTP (history, size, patient population, proportion of patients 
enrolled in Medicaid, types of services provided, any somatic or primary health care services 
provided, etc.)? 
 
2. How you describe your OTP in terms of its similarities or differences from other OTPs in 
Maryland (e.g., size, location, services provided, financing, etc.)? 
 
3. Does your OTP engage in information-sharing about best practices and lessons learned with 
other OTPs in Maryland? About what sorts of topics? 
 
4. What have you heard about Medicaid health homes in Maryland? Where have you obtained 
this information (e.g., state, other OTPs, professional associations like MATOD, etc.)? 
 
5. Has your OTP considered applying to become a health home? What factors have influenced 
the OTP’s decision not to apply to become a health home at this point? 
 
6. Do you think OTPs are an appropriate setting for implementing a health home? 
 
7. How familiar are you with the Medicaid reimbursement for health home services? Do the 
terms seem feasible for implementing the health home?  
 
8. What relationships with primary care providers and medical specialists in the community 
does your OTP already have?  
 
9. Do you already provide some of the health home services (e.g., care coordination, health 
promotion, etc.)? 
 
10. Do you think the health home is more appropriate for certain types of OTPs or geographic 
settings (e.g., community-based, hospital-based, county-based, in urban or rural or suburban 





11. What barriers exist to implementing a health home at this time (e.g., disinterest, no leader, 
financial limitations, lack of partnerships with primary care providers, lack of information on 
how to become a health home, etc.)? 
 
12. Why do you think so few OTPs in Maryland have become health homes? 
 
13. What additional support could the Maryland Medicaid office provide to OTPs that serve 
Medicaid patients? 
 
14. What might DHMH do to help more OTPs implement a health home? 
 
15. Is there anything I missed that you want to share about your OTP or the health home 
demonstration? 
 
16. Is there anyone that you would recommend I talk to about this topic? 
 
 
Maryland State Government Interview Guide 
 
1. Briefly describe your role at DHMH and your office or division’s role in supporting the 
health home demonstration. 
a. What are the responsibilities of [DHMH Behavioral Health Administration / Medicaid] in 
supporting the health home demonstration?  
b. How would you differentiate the roles and responsibilities of BHA and Medicaid with respect 
to the health home demonstration? 
 
2. Implementation: Describe the roll-out of the Medicaid health home demonstration from the 
beginning of your involvement with this initiative. 
a. How did the state promote adoption of the health home among OTPs?  
b. Did you target specific OTPs that seemed as though they would be good candidates for 
implementing a health home? If so, how did you identify these OTPs? 
c. What factors influenced the decision to implement opt-in rather than opt-out enrollment? 
d. What type of technical assistance have you provided to those OTPs implementing or 
interested in implementing a health home? 
e. What criteria has the state used to evaluate OTPs during the health home approval process?  
f. What challenges has the OTP component of the health home demonstration faced to-date? 
g. What have been the lessons learned to-date with respect to the OTP component of the health 
home demonstration? 
 
3. Sustainability: What are the prospects for sustainability of health homes in Maryland beyond 
these initial two years of enhanced federal matching?  
a. Will this affect reimbursement to OTPs for health home services? 
b. Are there efforts underway to encourage additional OTPs to become health homes? 
 
4. Monitoring: How is the state monitoring the implementation of health homes among OTPs?  
a. What type of data is being collected? (Who collects this data? Use of eMedicaid?) 
b. How does DHMH and Medicaid divide responsibilities for the monitoring process? 
c. Is the monitoring process dynamic? Do OTPs have access to information or summary reports 
to engage in ongoing quality improvement with respect to the health home? 
 
5. Evaluation: By what metrics will the state assess the effectiveness of the health home 





6. Context: How does the health home program fit within broader efforts to integrate behavioral 
health services and somatic care in Maryland?  
a. What was the thinking behind the transition to the carve-out Value Options while DHMH 
also integrated behavioral health services administratively? 
 
7. How would you describe the health home demonstration in Maryland currently in terms of its 
status in the implementation process (e.g., early implementation, implementation in progress, 
implementation complete, etc.)? 
 
8. What are the state’s plans for the health home demonstration among OTPs within the next 2-5 
years?  
 
9. Is there anything I missed that you want to share about the OTP health homes? 
 
10. Is there anyone that you would recommend I contact about the OTP health home 
demonstration? 
 
Additional questions (if time) 
 
1. How often does internal staff at [Maryland Medicaid / BHA] communicate with one another 
and meet formally about the health home demonstration? 
 
2. How often does staff at [Maryland Medicaid / BHA / SOTA] communicate or meet with OTP 
health homes?  
 
3. Can you tell me about the health home advisory committee? 
a. Who is represented on the Health Home Advisory Committee? 
b. What is the function of the Health Home Advisory Committee? 
c. What activities has the committee engaged in to-date? 
d. What future activities are planned? 
 
4. What sort of contact have you had with OTPs during the health home demonstration so far? 
a. Have any formal processes been established for soliciting OTP feedback? 
b. What sorts of questions or concerns have OTPs raised regarding the health home 
demonstration? 
c. Has [Maryland Medicaid / BHA] been in contact with non-participating OTPs? What sorts of 
explanations have these OTPs provided for not participating in the health home program? 
 
5. What do you see as the major barriers facing OTPs in terms of participating in the health 
home demonstration? 
 
6. What do you view as the major factors inhibiting participation in the health home 
demonstration among OTPs? 
 
7. What characteristics distinguish OTPs that applied to become health homes from those that 
did not?  
 
8. How would you describe a successful health home implementation? What factors do you 
view as critical to the successful implementation of health homes in OTPs?  
 
9. Have you engaged in information-sharing with state officials in Vermont or Rhode Island 
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Research Assistant to Dr. Colleen Barry and Dr. Emma McGinty, May 2013-Present 
 Collaborated on quantitative content analysis of the U.S. news media’s coverage of 
prescription opioid abuse during the period 1998-2012. 
 Assisted in development of 2014 nationally representative public opinion survey of 
knowledge and attitudes surrounding prescription opioid abuse, stigma toward people 
addicted to prescription opioids, and potential policy responses to reduce misuse of these 
medications. Conducted analysis of survey data. 
 Contributed to development of message framing experiment assessing public attitudes related 
to naloxone to prevent overdose. 
 Supported development of 2015 public opinion survey of knowledge and attitudes 
surrounding safe home practices among adults who have used prescription opioids in the last 
year and have children living in the home. 
 Conducted multiple interrupted time series study to assess impact of Florida policies targeting 




 Project tasks have included: instrument development, data analysis and interpretation, and 
manuscript preparation. 
 
Research Assistant to Dr. Craig Pollack, Jan 2013-Present 
 Participated in set of studies focusing on Maryland public housing population that: examine 
how caretakers' social networks influence children's mental and physical health outcomes; 
assess impact of dispersed v. clustered public housing on health composition of children’s 
social networks; assess how the diversity of children’s social networks influences BMI and 
obesity status; and explore how different measures of socioeconomic status relate to health in 
this vulnerable population. 
 Project tasks have included generating study questions, identifying appropriate study design, 
conducting data analysis, and preparing manuscripts for publication.   
 
Evaluator, Behavioral Health Systems Baltimore, November 2014-present 
 Independent evaluator of Chrysalis House Healthy Start, a program that aims to prevent 
recidivism and improve mother and child outcomes by providing diagnostic, treatment and 
transitional services to pregnant offenders with mental health and substance use disorders 
 Tasks include: conducting structured interviews with program participants, reviewing 
program materials, and preparing monthly and annual reports for Maryland’s Department of 
Health and Mental Hygiene and Behavioral Health Systems, Baltimore 
 
Research Assistant to Dr. Roland Thorpe, Jan-June 2014 
 Conducted analyses of data from National Health Interview Survey and Exploring Health 
Disparities in Integrated Communities Study-Southwest Baltimore (EHDIC-SWB) on racial 
disparities in health behaviors among men and the role of racial residential segregation.  
 Collaborated on manuscript development. 
 
Research Assistant to Dr. Leiyu Shi, June - August 2012 and 2013 
 Conducted literature reviews on various issues related to the primary care infrastructure and 
the impact of the Affordable Care Act on primary care, the health safety net workforce, 
insurance coverage, and disease management. 




Health Policy IV: Research and Evaluation Methods for Health Policy Teaching Assistant, 2013-
2014  
Led lab sessions, helped to develop new course assignments, worked with students to develop 
final papers, and graded student assignments.  
 
The Research and Proposal Writing Process I Teaching Assistant, 2013-2014  
Supported course logistics, provided student feedback, and led multiple sessions on proposal 
development. 
 
Introduction to Methods for Health Services Research and Evaluation Teaching Assistant, 2013  
Oversaw multiple lab groups, provided feedback to students, and graded student assignments. 
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Rustavi, Republic of Georgia 
 Served as: English teacher in local school; trained teachers in pedagogy and computer 
applications; chair of public health promotion committee; organized women’s health 
education fair involving 16 non-governmental organizations; and led school sanitation 
improvement project. 
 Grand awards: USAID Small Projects Assistance Grant, Peace Corps Partnership Program 
Grant, Appropriate Projects (Water Charity) Grant  
 
NORC at the University of Chicago, Health Research Division, July 2006 - May 2009 
Research Analyst, Jan 2008 – May 2009  
Research Assistant, July 2006 - Dec 2007 
Bethesda, MD 
 Supported survey and interview protocol development; collected and analyzed qualitative 
data; conducted literature reviews; prepared Internal Review Board (IRB) applications; 
assisted in presentations at professional meetings; prepared research proposals and project 
reports; provided technical assistance to federally-funded grantees; and collaborated with 
clients.  
 Project work funded by: U.S. Department of Health and Human Services (DHHS) Agency for 
Healthcare Research and Quality (AHRQ), Health Resources and Services Administration 
(HRSA), Office of Minority Health (OMH) and the Office of the Assistant Secretary for 
Planning and Evaluation (ASPE); National Association of County and City Health Officials 
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Stigma toward persons with prescription opioid addiction and public support for punitive and 
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